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CD  –  cluster of differentiation 
CLL  –  chronic lymphocytic leukemia 
CNS  –  central nervous system 
CR  –  complete remission 
Cy-5  –  indodicarbocyanine 
DC  –  dendritic cells 
Dexa/Vcr –  dexamethasone/vincristine 
DLBCL  – diffuse large B-cell lymphoma 
DNA  –  deoxyribonucleic acid 
EBV  –  Epstein-Barr virus 
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FACS  – fluorescent activating cell sorter 
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FCM  –  multiparameter flow cytometry 
FISH  –  fluorescence in situ hybridization 
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LG-NHL  –  low-grade non-Hodgkin’s lymphoma 
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mDC  –  myeloid dendritic cell subset 
MDS  –  myelodysplastic syndrome 
MFI  – mean fluorescence intensity 
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MRD  –  minimal residual disease 
MTX  –  methotrexate 
My  –  myeloid marker 
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NHL  –  non-Hodgkin’s lymphoma 
NIH  –  National Institute of Health, U.S.A. 
NK  – natural killer 
NK-NHL  –  natural killer-cell non-Hodgkin’s lymphoma 
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Multiparameter flow cytometry (FCM) is a powerful laser-based technology 
that is used to characterize a cell and its characteristics. In haematology FCM is 
widely used and has become the integral part of diagnostic work-up of 
lymphoid as well as myeloid malignancies. Malignancies are classified into four 
major categories, according to the tissue and cell types from which they arise: 
malignancies derived from epithelial cells (carcinomas), from connective tissue 
or muscle cells (sarcomas), from haematopoietic tissue (leukemias and 
lymphomas) and malignancies derived from cells of the nervous system. By 
current concept, malignancies originate from a single cell that has undergone a 
specific genetic change that enables it to outgrow its neighbors (Hanahan and 
Weinberg, 2000). It also means that malignancies are clonal. Malignancies of 
haematopoietic system are different from other tumors as far as their evolution 
and dissemination are not as dependent on angiogenesis, architectural disruption 
and metastatic processes that are critically involved in most other malignancies 
(Graves et al., 1986). Haematological malignancies originate from cells of the 
bone marrow (BM) and the lymphatic system. Three major forms of haemato-
logical neoplasms are leukemias, lymphomas and plasma cell neoplasms. The 
number of new patients in Europe diagnosed with haematological malignancies 
can be estimated in approximately 230 000 patients. The new cases of leukemia, 
lymphoma and myeloma account for 8% of all the new cancer patients diag-
nosed in Europe and the estimated deaths from the haematological malignancies 
account for 7% of the cancer-related deaths. The overall incidence of 
haematological malignancies appears to be rising (Rodriguez-Abreu et al., 
2007). Peripheral blood and BM are ideal sources of material for FCM studies 
due to natural suspension of cells. Lymphoid cells are also easily available from 
lymph nodes and aspiration material. This feature is the basis for popularity of 
FCM in haematology. Although FCM has been traditionally used to determine 
lymphoid cells of the immune system, the development of the method including 
the possibility of detecting intracellular antigens has broaden the applicability of 
FCM considerably. It is possible to detect by FCM intracellular proteins that 
regulate the cell homeostasis and critical biochemical pathways. Another 
excellent feature of FCM is the power to detect small cell populations at 
submicroscopic level and give quantitative results. In practical terms this allows 
more precise evaluation of treatment response and patient stratification in order 
to choose the most optimal treatment modality. Finally, with development of 
antibodies it is possible to explore new important cell types in haematopoietic 
system, which co-ordinate immune system and may even play an important role 








REVIEW OF THE LITERATURE 
1. Flow cytometry 
Cytometry is defined as the measurement of cells. Nowadays FCM is capable of 
rapid, accurate and reproducible measurement of cell properties at high speed. 
The most widely used clinical application of FCM in haematology is the 
classification of haematopoietic cells by cell surface antigens. However, there 
are many other applications and approaches of FCM such as analysis of DNA, 
studies of cell proliferation and death, RNA and protein content, calcium ions, 
kinetics of intracellular enzymes, microbiology and biotechnology analysis. 
These applications are more specifically described in the “Bible of FCM” 
written by H.M. Shapiro (Shapiro, 2003).  
 
 
1.1. History of flow cytometry 
Significant achievements in the development of FCM capabilities are given in 
Table 1. 
 
Table 1. A brief description of achievements in the development of FCM. 
Year Development 
1934 Photoelectric measurement of cells in a capillary 
1941 Development of fluorescence antibody technique 
1947 Photoelectric particle counting 
1949 Particle counting by Coulter volume 
1953 Hydrodynamic focusing for reproducible delivery of cells in a fluid 
1955 Automated scanning instrument for screening cytological smears 
1956 High speed automatic counting by Coulter volume 
1961 First use of fluoresence for quantitation 
1964 Electrostatic principle for ink jet 
Acridine orange differentiation of leukocytes 
1965 Cell sorting 
Particle separator in principle capable of separating by volume, optical 
density, or fluoresence 
Spectrophotometry of cells 
1967 The 1’st paper of fluoresence flow cytometry 
1968 Automated imaging 
Fluorescence flow cytometry patent 
Flow vs scanning for cancer cytology 
1969 The 2nd, 3rd and 4th paper of fluoresence flow cytometry 
The 1st paper describing light scatter 
1972 Fluorescence-activated cell sorting 
1973 Doublet discrimination patent 
1974 Mathematical analysis of DNA distributions 




1977 The first use of monoclonal antibodies in flow cytometry 
Two-color fluoresence compensation 
1978 Radiation collector methods – three patents 
1979 The second use of monoclonal antibodies in flow cytometry 
Flow imaging 
Patent of the radiant energy reradiating flow cell system  
1982 Slit-scanning flow cytometer 
1984 Convention of nomenclature for DNA cytometry – analysis guidelines 
Proposal for data file standard (FCS 1.0) 
Three-color immunofluorescence 
1987 Time as a quality control parameter 
Dual-beam high-speed sorting 
1988 4 pi light collection flow chamber – increased sensitivity 
1990 Data file standard (FCS 2.0) 
1991 Barcode reader – first automation of flow cytometry for clinical systems 
1995 Five-color flow cytometry 
1997 Eight-color, ten parameter flow cytometry 
1997 Data file standard (FCS 3.0) 
2001 Eleven-color, 13 parameter flow cytometry 
2004 Seventeen-color flow cytometry 
2006 Quantum dots in flow cytometry 
2010 Data file standard (FCS 3.1) 
 
 
The first important publication, which could be argued as the foundation of cell 
analysis, was published by Moldovan (Moldovan, 1934). This was the first 
attempt to count or measure cells flowing in suspension. Basically he used 
microscope that was focused on a capillary glass tube through which a forced 
suspension of cells, recording the passage of each cell by a photoelectric device 
at the eyepiece. It is also believed that the basis of modern analytical cytology 
was established by Torbjorn Caspersson in 1941 in Stockholm who showed that 
nucleic acids were necessary prerequisites for the protein synthesis in the cell. 
These studies were performed by using cadmium spark source for ultraviolet 
light and electronic circuits for detection of signals. The next important 
discovery was made in 1940s were Coons and coworkers (Coons et al., 1941) 
developed the fluorescent antibody technique. Further, in 1950 Coon and 
Kaplan reported a new fluorochrome, fluorescein, conjugated in isocyanate. 
This was the first definitive fluorochrome used at present day. In 1953 P.J. 
Crosland-Taylor published the sheath-flow principle used to present day in 
almost all flow cytometers (Crosland-Taylor, 1953). He showed that the 
clogging could be prevented by using a large diameter channel and centering the 
cell stream in a fluid sheath using the principle of laminar flow. Probably the 
key inventor in flow cytometry was Wallace H. Coulter. His first commercial 
Coulter ® Counter was marketed in 1956 in which an electronic measurement 




1956). This instrument was able to give an immediate blood cell count and 
utilized a very small volume of blood. Electrostatic cell sorter was invented by 
Mack Fulwyler in 1965 (Fulwyler, 1965). In 1965 Louis Kamentsky and 
coworkers were able to minimize the clogging by using a bowtie shaped 
channel and built the first multiparameter flow cytometry. As the next step, in 
1967 Kamentsky and Melamed elaborated on Moldaven’s method of forcing 
cells through a capillary tube and designed a sorting FCM (Kamentsky and 
Melamed, 1967). At the same time Marvin Van Dilla at Los Alamos was 
interested in cell cycle studies and identified fluorescence signals as a promising 
approach. He was the first who publicly reported on January 23, 1968 the 
results of fluorescence measurement including DNA histogram (Sack, 2009). 
Parallel in Europe, Wolfgang Göhde in Germany, inspired of the work of 
Caspersson, designed in 1969 the first commercially available flow Cytometer, 
the ICP-11 Impulscytophotometer sold by Phywe, Göttingen (Sack, 2009). 
Another one of the most important cytometry’s pioneers is Leonard 
Herzenberg at Stanford University. His work led to the commercialization of 
cell sorters by Becton Dickinson (BD). In short, Herzenberg had obtained an 
National Institute of Health, U.S.A. (NIH) grant to build up two machines, one 
for NIH and one for Stanford. Bernie Shoor, a long-time BD employee, worked 
out an agreement with Herzenberg to have BD actually build the instruments. 
BD negotiated a license and built both machines, called Fluorescence-Activated 
Cell Sorter (FACS)-1, which were delivered in early 1973 (Sack, 2009). The 
next important date is 1975 when Köhler and Milstein introduced monoclonal 
antibodies (moAb) technology, which provided the basis for highly specific 
immunological reagents for use in cell studies (Köhler and Milstein, 1975). At 
the same year, in early 1975, NIH ordered from Mack Fluwyler to build a large 
multiparameter sorter to the National Cancer Institute. This machine EPICS II 
(Electronically Programmable Individual Cell Sorter) was shipped in July 1975 
(Sack, 2009). 
It was a fundamental progress to the field of cytometry when Loken et al 
defined the process of spectral overlap using two-color analysis (Loken et al., 
1977). This process was subsequently repeated as each color was added to rise 
the number of simultaneous colors up to 17 (Perfetto et al., 2004). However, in 
clinical samples the usage of panels with 8–10 colors seems to be sufficient. 
An important milestone in the history of cytometry was the creation of the 
Flow Cytometry Standard (FCS) format opening thus the field to those outside 
of the major companies (Murphy and Chused, 1984). The FCS standard 
transformed the field of cytometry. Over the years FCS has been continuously 
updated from FSC 1.0 to FSC 3.1 protecting thus the stability and accuracy of 
the entire field (Spidlen et al., 2010).  
The first International Workshop on Human Leukocyte Differentiation 
Antigens was held in 1984 (Bertrand et al., 1984). This and following work-
shops defined antigens on leukocytes and other cells and allocated cluster of 




1.2. The beginning of clinical cytometry 
DNA analysis was a natural application for clinical cytometry and it was 
assumed from early days with work of Van Dilla that this would have a great 
clinical significance. However, the majority of clinical applications were 
focused on lymphocyte and lately leukocyte phenotyping. The study of 
lymphocytes was heavily influenced by the discovery of moAbs in 1975 
(Köhler and Milstein, 1975). 
Over the past 40 years, it has been a well-defined periods of technology 
development. The 1950s was the decade of cell counting, the 1960s the 
emergence of cell sorting, the 1970s the fluorescence, the 1980s the second 
period of sorting and from the 1990s the era of multicolor fluorescence with re-
emerge of high-speed cell sorting with low-cost analyzers. The next generation 
instruments will probably come a tool for the masses and this will be the 
ultimate success for flow cytometry (Sack, 2009). 
 
 
1.3. The principles of flow cytometry 
FCM scans single cells or particles as they flow in a liquid medium past an 
excitation light source. The basic principle of FCM is that light is scattered and 
fluorescence is emitted as light from the excitation source strikes the moving 
particles. 
A basic FCM consists of a source of light, a flow cell, optical components to 
focus light of different colors on to the detectors, electronics to amplify and 
process the resulting signals digitally with a computer. This process can be 
described as four interrelated systems, shown in Figure 1. 
In flow cytometer the cells are moving in a liquid linear stream through the 
laser beam, passing the beam one at the time. This is achieved by hydrodynamic 
focusing. As the cell passes through the laser beam, light is scattered in all 
directions and fluorescence signals are elicited. Cells are counted and partly 
identified by differential light scatter. 
Computer analysis is based on size (FSC), granularity (SSC) and whether the 
cells are carrying fluorescent molecules either in forms of antibodies or dyes. 
Photo-detectors convert the light signals to electric impulses, which are 
processed and analyzed. Fluorescence occurs when a fluorescent molecule 
absorbs light at one wavelength, reaches an excited state and then returns to the 
ground state, emitting light at longer wavelength. Argon lasers, which are the 
most common light source in FCM, produce monochromatc light at 488 nm, 








Figure 1. General structure of flow cytometer. 
 
Adapted from Brown and Wittwer, 2000. 
A single cell suspension is hydrodynamically focused with sheath fluid to intersect an argon-ion 
laser. Forward side scatter (FSC) is detected as a correlate of cell size. Dichroic mirrors and filters 
are spectrally separating side-scatter (SSC) as a measure of granularity (detector 1) and 
fluorescence signals (detectors 2–4). The light signals are amplified and data of each cell is 
converted to digital form by photomultipliers for analysis and display on a computer screen. 
 
 
1.4. Standardization in flow cytometry 
The intra- and inter-laboratory reproducibility of a test must be achieved and 
optimized in order to become a diagnostic laboratory test. However, there are a 
wide range of different reagents and methods used for sample preparation, data 
acquisition and analysis of FCM immunophenotyping (Bènè et al., 1995; Hasset 
and Parker, 1995; Homburger et al., 1993; van’T Veer et al., 1992). Therefore 
consensus protocols, data interpretation and reporting for leukemia and 
lymphoma immunophenotyping are needed. 
A Concerted Action in EU Biomedical and Health research program started 
in 1994 and was the first international study in the field of diagnosis of minimal 
residual disease (MRD), the disease level which is not detectable by con-
ventional light microscopy. The following centers participated: Department of 
Immunology, Erasmus University and University Hospital, Rotterdam and 
Dutch Childhood Leukemia Study Group, The Hague, The Netherlands; 
Karolinska Hospital, Stockholm, Sweden; M Tettamanti Research Center, 
Monza, Italy and Portuguese Institute of Oncology, Lisbon, Portugal. The aims 
were an investigation of MRD in acute leukemias and development of 




At present, EuroFlow, a scientific consortium takes and effort to develop 
new tools for fast, sensitive and standardized tools for diagnostics of haemato-
logical malignancies. EuroFlow consortium consists of ten diagnostic research 
groups from the Netherlands, Spain, Portugal, Germany, France, Czech 
Republic, Poland and Belgium. The major aim of this project is to publish 
optimized and standardized immunostaining protocols for the diagnosis, 
classification, and prognostic subclassification of haematological malignancies 
as well as for detection of MRD during follow-up. 
Another important institution, which has worked for FCM standardization is 
European Leukemia Net Foundation, Project 10: Diagnostics, lead by M.C. 
Béné and G. Zini. Several guidelines on normal BM analysis (Arnoulet et al., 
2010), myelodysplastic syndromes (van de Loosdrecht et al., 2009) and general 
recommendations (Béné and Kaeda, 2009) are published. 
 
 
1.5. How to use flow cytometry in practice to avoid errors 
To get reliable FCM results, it is generally important: 
 to maintain a clean fluidic system, drawing a 10–30% bleach solution 
followed by a distilled water to avoid carry-over effect 
 to adjust sample flow rates since too high rates during acquisition can result 
in lower data resolution 
 to avoid the production of aerosols in the fluidic system 
 to ascertain that all MoAbs and other reagents are compatible with the FCM 
 to select fluorochromes that can be detected using the optical configuration 
of the FCM and understanding that emission spectra overlap contributes to 
detection, which can be used to guide fluorochrome selection in multicolor 
analysis 
 to determine which parameters will be used for acquisition, to decide which 
appropriate control samples will be used and what type of data analysis will 
be performed 




2. Classification of Haematopoietic malignancies 
The the World Health Organization (WHO) classification of haematological 
malignancies stratifies neoplasmas primarily according to cell lineage: myeloid, 
lymphoid, histiocytic/dendritic cell and mast cell. According to the WHO, 
lymphomas are classified in the principle of distinct ckinical entities (Jaffe, 
2001). For this all available information has generally to be used, including 
morphology, immunophenotype, genetic and clinical data. However, morphology 





Lymphomas are malignant clonal proliferation of lymphocytes. Lymphomas are 
divided into two major categories (Jaffe, 2001): Hogkin’s lymphoma and non-
Hodgkin’s lymphoma (NHL). 
Non-Hodgkin’s lymphoma is divided: 
 B-cell non-Hodgkin’s lymphoma (B-NHL) 
 T-cell non-Hodgkin’s lymphoma (T-NHL) and natural killer (NK)-cell 





The most common lymphoma worldwide is B-NHL. B-cell lymphomas 
compromise over 85% of NHLs and approximately 4% of new cancers cases 
around the world. B-NHLs are more common in developed countries, 
particularly in the United States, Europe, Australia and New Zealand. The 
annual incidence of B-NHL ranges from 1.2/100 000 in China to over 15/100 
000 in the United States, with intermediate incidence rates in South America, 
Africa and Japan. Two most common types are large B-NHL and follicular 
lymphoma (FL), which compromise 50% of all NHLs. The individual B-NHLs 
vary in their relative frequency in different areas of the world. FL is more 
common in developed countries, particularly in the United States and Western 
Europe, and is uncommon in Eastern Europe, Africa and Asia. Burkitt 
lymphoma (BL) is endemic in equatorial Africa, where it is the most common 
malignancy of childhood, but compromises only 1–2% of lymphomas in 
Western Europe and in the United States (Jaffe, 2001). The incidence of 
lymphoma in Lithuania as a representative of Baltic region is presented in Table 
2 (Griškevičius, et al., 2007). The median age for all types of B-NHLs is 60–70 
years, but BL has a median age in adults of 30 years. 
 
Table 2. Lymphoma in Lithuania – retrospective analysis 2004–2006. 
Subtype Proportion of cases (%) Incidence /100 000 
Diffuse Large B Cell 52.77 3.81 
Small lymphocytic 9.61 0.69 
Mantle cell 8.21 0.60 
Marginal zone 6.63 0.48 
Peripheral T, unspecified 5.28 0.38 
Follicular 4.33 0.31 
Primary mediastinal 2.44 0.18 
Burkitt lymphoma 2.17 0.16 
Mycosis fungoides 1.62 0.12 
Angioimmunoblastic T 1.49 0.11 
Anaplastic large cell 1.35 0.10 





Infectious agents are associated with the development of several types of B-
NHLs. Epstein-Barr virus (EBV) is present in nearly 100% of endemic BL 
(Prevot et al., 1992) and in 40% of sporadic and HIV associated cases 
(Hamilton-Dutoit et al., 1993). EBV is commonly involved in the pathogenesis 
of the majority of B-NHLs arising in iatrogenically immunosupressed patients. 
Human herpesvirus-8 (HHV8) /Kaposi sarcoma herpesvirus is associated in the 
pathogenesis of primary effusion lymphoma and the lymphomas associated with 
Castelman disease in HIV-infected patients (Cesarman et al., 1995). Hepatitis C 
virus is implicated in lymphoplasmocytic lymphoma associated with type II 
cryoglobulinemia (Agnello et al., 1992) and with some lymphomas of the liver 
and salivary glands (Ascoli et al., 1998). Gastric MALT lymphomas with 
H. pylori infection depend on the presence of H. pylori activated T cells and 
these lymphomas may respond to antibacterial treatment (Wotherspoon et al., 
1993). B. burgdorferi has been implicated in the pathogenesis of cutaneous 
MALT lymphoma (Cerroni et al., 1997). 
The major risk factor for B-NHLs is considered an abnormality of the 
immune system, either immunodeficiency or autoimmune disease. Although in 
most patients with B-NHLs immune system abnormalities are not found, 
immunodeficient patients have a markedly increased incidence of B-cell 
neoplasia, particularly large B-cell lymphoma and BL. Major forms of 
immunodeficiency are at present infection with HIV, iatrogenic immuno-
supression to prevent allograft rejection or graft versus host disease. Hashimoto 





Three B-NHLs have characteristic genetic abnormalities that are important in 
determining their biologic features and that are useful for differential diagnosis. 
These include: t(14;18) in FL, t(11;14) in MCL and t(8;14) in BL. Cha-
racteristic for these translocations is that a cellular proto-oncogene is placed 
under the control of the immunoglobulin promotor on chromosome 14q, 
resulting in constitutive activation of the gene which in turn gives to the cell 
survival or proliferative advantage. In FL, t(14;18) translocation results in over-
expression of an anti-apoptosis gene Bcl-2. In MCL and BL, the translocations 
result in over-expression of cell cycle genes associated with proliferation Cyclin 




Immunophenotyping of lymphoma cells is essential in lymphoma diagnostics 





combination of morphologic features and a panel of antigens is necessary for 
the correct diagnosis. In some cases, clinical knowledge is essential, such as 
marginal zone lymphoma of MALT type versus nodal or splenic marginal zone 
lymphoma, and mediastinal large B-cell lymphoma (Jaffe, 2001). In difficult 
cases cytogenetic, molecular genetic and/or fluorescence in situ hybridization 
(FISH) analyses are mandatory. These techniques are used to determine 
clonality and specific genetic rearrangements characteristic to lymphoma 
subcategories. 
Therefore correct lymphoma diagnosis is based on: 
 Morphology 
 Immunophenotype 
 Cytogenetics and/or FISH 
 Molecular genetics. 
 
Immunophenotyping is used to distinguish the lymphomas of small cell types 
from reactive hyperplasia (RH) and the proliferating lymphomas from non-
lymphoid tumors. Immunophenotyping is also used to subclassify morpho-




In the WHO classification, B-NHLs are listed according to their major clinical 
presentations: 
1)  Predominantly disseminated lymphoma/leukemia 
 CLL/small lymphocytic lymphoma 
 Lymphoplasmocytic lymphoma/Waldenström’s macroglobulinema 
 Hairy cell leukemia 
 Splenic marginal zone lymphoma 
 Plasma cell myeloma. 
 
In general, these lymphomas have relatively indolent clinical course but present 
with disseminated disease. The usual sites of involvement are BM with or 
without peripheral blood and solid tissues such as spleen or lymph nodes. 
 
2) Primary extranodal lymphomas 
 MALT lymphomas. 
 
MALT lymphomas virtually always present in extranodal sites, and probably 
correspond to normal lymphoid cells specific for extranodal immunologic 
reactions. These lymphomas less likely disseminate, and if they do, the dissemi-






3) Predominantly nodal lymphomas 
 FL (Figure 2) 
 Mantle cell lymphoma (MCL) 
 Nodal marginal zone lymphoma (NMZL) 
 Diffuse large B-cell lymphoma (DLBCL) 
 BL. 
 
These lymphomas typically present with disseminated disease involving pre-
dominantly lymph nodes, but with frequent involvement of BM, spleen and 
liver. They also may involve other extranodal sites, but rarely present with 
localised extranodal disease. FL and NMZL are low-grade lymphomas with 
indolent clinical course. MCL has been recognized relatively recently. MCL can 
be classified as indolent lymphoma since its survival is in years, but its median 
survival is significantly shorter than that of FL. 
DLBCL and BL are aggressive B-NHLs, which may present with either 
nodal or extranodal disease and may be either localized or disseminated. 
DLBCL is the most common lymphoma worldwide, accounting approximately 
30% of the cases. Patients typically present with rapidly growing masses at a 
localized nodal or extranodal site. An important clinical subtype of DLBCL is 
primary mediastinal (thymic) large B-cell lymphoma. This is an aggressive 
lymphoma of young adults with a slight female predominance. Distinctive 
clinical entities of DLBCL are also primary effusion lymphoma and intra-
vascular lymphoma. Morphological variants of DLBCL are: centroblastic, 
immunoblastic, T-cell rich and anaplastic. 
BL is a highly aggressive lymphoma. Typically rapidly proliferating B cells 
are medium-sized and bearing translocations resulting in deregulation of the c-
myc oncogene. Major clinical subtypes of BL are: endemic, sporadic and 
immunodeficiency-associated. Some cases that have morphologic features 
intermediate between typical BL and DLBCL are called “Burkitt-like”. In the 
WHO classification this category is a subtype of BL, so-called atypical 
Burkitt/Burkitt-like lymphoma (Jaffe, 2001). 
Illustration of Follicular lymphoma. (A) Touch imprint cytology shows 
predominantly small to medium-sized cells centrocytes (   ) with cleaved nuclei 
and occasional large cells (  ) called centroblasts (May-Grünwald-Giemsa, 
original magnification x 10). (B). Immunophenotype of kappa positive follicular 
lymphoma cells (red dots). Follicular lymphoma cells were positive for CD10, 






Figure 2. Cytology and immunophenotyping of Follicular lymphoma. 
 
 
Treatment and outcome 
Natural history and sensitivity to treatment of the B-NHLs are extremely 
heterogeneous. Therefore the correct diagnosis is essential to predict clinical 
outcome and direct therapy. Patients with indolent lymphomas such as CLL, FL 
and plasma cell myeloma are considered incurable and may be observed 
without therapy until patients become symptomatic. The median survival 
exceeds generally five or more years. 
Treatment options are: radiotherapy, chemotherapy, immunochemotherapy 
and radioimmunochemotherapy. Localized MALT lymphoma may be cured 
with radiotherapy. MCL combines features both of indolent and aggressive 
lymphomas and is considered at present incurable, with a median survival of 
three years. However, treatment protocols incorporating high dose arabino-
furanosyl cytidine (Ara-C) and autologous transplantation seems promising 
(Geisler et al., 2008). In certain B-NHLs such as FL or hairy cell leukemia bio-
logical agent -interferon could be effective. The exact cell-death mechanism of 
-interferon is not fully elucidated since interferons have multiple actions 
including antiproliferative, apoptotic and anti-angiogenic effects. Furthermore, 
interferons have ability to modulate an immune response specifically activating 
cytolytic T cells and NK cells. Hairy cell leukemia is also responsive to 
pentostatin or cladribine with excellent treatment results. Long-term survival 
could be achieved in 80% of patients (Else et al., 2009). High rates (87%) of CR 
in FL have been achieved with radioimmunotherapy with yttrium-90 
ibritumomab tiuxetan (Morschhauser et al., 2008). The most powerful treatment 




cyclophosphamide and rituximab. Treatment response is achieved over 90% of 
patients (Hallek et al., 2010; Tam et al., 2008). Waldenström’s macro-
globulinemia is responsive to bendamustine (Treon et al., 2011). 
In paradox, aggressive high-grade lymphomas are potentially curable. 
Currently approximately 40% of DLBCL are cured with aggressive chemo-
immunotherapy containing adriamycin (Coiffier et al., 2010). The back-bone of 
chemotherpay is usually CHOP regimen consisting of cyclophosphamide, 
adriamycin, vincristine and prednisolone. If lymphoma cells are CD20 positive, 
then monoclonal antibody against CD20, rituximab is usually added to CHOP. 
This immunochemotherapy regimen, R-CHOP is administrated every three or 
two weeks, named R-CHOP 21 or R-CHOP14, respectively. If lymphoma cells 
are CD20 negative, adding of etoposide (CHOEP) is an option (Wunderlich et 
al., 2003). BL is highly aggressive and is treated with more aggressive 
chemotherapeutic regimens, including rituximab (Oriol et al., 2008). 
The future is directed to investigate potential genetic targets (Alizadeh et al., 
2000). Close cooperation between haematologists and pathologists is essential 
for the future progress in the cure of lymphomas. 
 
 
2.1.2. T-NHL and NK-NHL 
T-NHLs are derived from mature or post-thymic T cells. Because NK cells are 
closely related and share some functional and immunopheotypic properties with 
T cells, WHO classification considers NK-NHL together with T-NHL (Jaffe, 
2001). These lymphomas are relatively uncommon, comprising approximately 
12% of all lymphomas (Anon et al., 1997). Clinically, T-NHLs and NK-NHLs 
are one of the most aggressive lymphomas with some exceptions such as 
Mycosis fungoides or ALK-positive anaplastic large cell lymphoma. Aggressive 




2.2. Acute leukemias 
Acute leukemia (AL) is a malignant disorder of haematopoietic cell precursors, 
which manifest as a clonal expansion of malignant blasts in BM, blood or other 
tissues. AL is divided into two categories depending on the origin of the neo-
plastic cells: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia 
(AML). ALL is characterized by proliferation of lymphoblasts that originate 
from a lymphocyte progenitor cell. AML originates from the myeloid haemato-
poietic progenitors, which include myeloblasts, monoblasts, erythroblasts and 
megakaryoblasts. The proliferative process may involve one or several of these 
precursor cells. 
Worldwide, the overall incidence of AL is approximately 4/100 000 per 





at median age 60 years and with an incidence of 10/100 000 per year in 
individuals older than 60 years. ALL is predominantly a disease of children, 
75% of cases are diagnosed below 6 years of age (Jaffe, 2001). The incidence 
peak of ALL is at age 2–7 years, where the incidence is as high as 10/100 000 
children per year (Schmiegelow and Gustafsson, 2005). The incidence of ALL 
is highest in the developed countries. The most common subgroups are B-cell 
precursor ALL with a t(12;21)(p13;q22) or a high-hyperdiploid genotype. The 
outcome for children is superior at the peak incidence years age 2–7 when 
compared to children in older or younger age groups (Schmiegelow and 
Gustafsson, 2005). 
In Estonia, during 1982–1996 the age standardized incidence rate regarding 
total acute de novo leukemias was 1.49/100 000 inhabitants for patients aged 
16–64 years and 5.31/100 000 for patients ≥65 years (Wennström et al., 2004; 




The aetiology and pathogenetic mechanisms of AL remain unknown in the vast 
majority of cases. The possible triggering factors associated with AML include 
ionizing radiation, previous cytotoxic chemotherapy with chlorambucil, cyclo-
phosphamide, melphalan, thiotepa, treosulphan, etoposide and benzene. Ciga-
rette smoking may increase the risk by two-fold. However, only 1–2% of the 
diagnosed AML can be related to these genotoxic agents (Jaffe, 2001). The 
aetiology of ALL is still largely unknown. Autosomal dominant and recessive 
cases of familial AL, in addition to associations with a variety of genetic 
syndromes including trisomy 21, Fanconi’s anaemia, ataxia teleangiectasia and 
Bloom’s syndrome are rare (Horowitz, 1997). 
 
 
2.2.2. Classification of acute leukemia 
The first widely used classification of AL was introduced in 1976 by the 
French-American-British (FAB) Cooperative group (Bennett et al., 1976) with 
modification in 1982 (Bennett et al., 1982) and 1985 (Bennett et al., 1985a; 
Bennett et al., 1985b). The FAB classification is based on morphological 
characteristics of the malignant cells in association with cytochemical stainings, 
immunophenotype and ultrastructural features.  
In purpose to highlight the prognostic relevance of the chromosomal 
abnormalities and the biologic features, the introduced WHO classification 
recognizes four AML categories (Jaffe, 2001): 
1) AML with recurrent genetic abnormalities 
2) AML with multilineage dysplasia 
3) Therapy-related AML and myelodysplastic syndrome (MDS) 





According to the FAB classification, ALL is divided into three morphologic 
types: L1, L2 and L3, defined by the cytologic features of the lymphoblasts in 
BM smears. 
According to the WHO classification, ALL is classified into two categories 
based on postulated cell of origin and malignant cell immunophenotype. 
1) Precursor B lymphoblastic leukemia/lymphoblastic lymphoma 
2) Precursor T lymphoblastic leukemia/lymphoblastic lymphoma 
 
Because of the biologic unity of ALL and lymphoblastic lymphoma, the use of 
one or the other term is in some occasions arbitrary. If the patients present with 
a mass lesion and 25% or fewer lymphoblasts in BM, the designation of 
lymphoma is preferred (Jaffe, 2001). Importantly, at present the cut-off limit for 
blast count for AML diagnosis is 20% according to WHO classification, as 
opposed to 30% required by historic FAB system. 
 
 
2.2.3. Prognostic factors in acute leukemia 
Many clinical features and laboratory parameters have been reported to have 
prognostic value in AL. At present, the most important prognostic factors both 
in AML and ALL are: (1) age of the patient, (2) the karyotype, (3) initial 
response to treatment and (4) WBC count at diagnosis (Bassan et al., 2004; 
Litzow, 2004; Schmiegelow and Gustafsson 2005). Recognition of further 
prognostic variables is important scientific task and will make possible to tailor 
treatment according to different risk-categories, to improve survival and to 
reduce treatment-related toxicity and mortality. 
 
 
Prognostic factors specific for AML 
According to Grimwade et al (Grimwade et al., 1998): AML could be divided 
into three prognostic categories by cytogentic abnormalities detected at 
diagnosis: 
 a favorable prognostic group – t(8;21), t(15;17), t(16;16) or inv(16); 
 an unfavorable prognostic group – complex karyotype, –5, del(5q), –7 or 
abnormalities of 3q; 
 an intermediate group – either normal karyotype or abnormalities not 
included in the other subgroups. 
 
In some studies abnormalities of 9q, 11q, 20q, 21q and t(9;22) or abnormality of 
7p are associated with a poor prognosis (Litzow, 2004). The good prognosis 
group is uniform but which cytogenetic abnormalities are included in the 
intermediate or poor risk categories, varies somewhat in various studies 




groups, based on cytogenetics and early treatment response (Wheatley et al., 
1999). However, the majority of AML patients display intermediate prognostic 
features with variable clinical outcome (Grimwade et al., 1998). Moreover, 
AML patients are considered to be in morphological complete remission (mCR) 
when BM samples contain 5% blasts, based on light microscope examination. 
In summary, there is an obvious need for more accurate treatment-related 
prognostic factors, which would help to improve outcome in AML patients. 
 
 
Prognostic factors specific for ALL 
The important feature is the extent of the disease – measured as adenopathy, 
organmegaly, CNS involvement or the presence of mediastinal mass (Borowitz 
and DiGiuseppe, 2001). Specific chromosomal aberrations are also associated 
with poor outcome (Schmiegelow and Gustafsson, 2005). According to the 
Nordic Society of Pediatric Hematology and Oncology (NOPHO) 2000-ALL 
study group, the following features defined poor prognosis (Schmiegelow and 
Gustafsson, 2005): 
1) WBC 50.1 x 109/l 
2) T-cell ALL 
3) CNS and/or testis involvement by leukemia 
4) The presence of 11q23, t(9;22), t(1;19) and/or hypodiploidy (<45 
chromosomes) 
5) poor/slow response to the induction treatment. 
 
Prognostic factors in adult ALL are less well defined. However, older age, high 
WBC count, lack of initial response to treatment and the presence of t(9;22) or 




2.2.4. AML treatment and clinical outcome 
Combination of Ara-C and the anthracycline daunorubicin introduced in the 
1960s and 1970s is considered as back-bone of AML treatment. At present, 
AML treatment could be divided into two phases (Stone, 2002): 
1) induction therapy 
2) post-induction therapy. 
 
Standard induction therapy consists of seven days Ara-C and three days of 
anthracycline, usually daunorubicin, but also with idarubicin or mitoxantrone. 
In some studies the third drug etoposide or 6-thioguanine is added (Kimby et 
al., 2001). The aim of induction treatment is to achieve CR, but to maintain CR, 
post-induction therapy is necessary. For patients younger than 60 years, 




(SCT) and intensive chemotherapy (Kimby et al., 2001). The optimal duration 
and number of cycles given in post-remission therapy is not clear. The latest 
data indicates that in younger adult patients who are not candidates for 
allogeneic SCT (allo-SCT), treatment by four courses of high-dose 
chemotherapy or by one course of high dose chemotherapy followed by 
autologous SCT (auto-SCT) results in improved survival rates (Farag et al., 
2005). Allo-SCT is considered as standard post-remission therapy only in poor 
risk patients (Kimby et al., 2001; Smith et al., 2004). With current induction 
treatment, CR achieved in 70–80% of adult patients younger than 60 years and 
five-year relapse free survival reach up to 40% (Stone, 2002; Löwenberg et al., 
2011). In older adults, CR is achieved in 30–50% of patients and median 
relapse-free survival (RFS) is only 9–12 months (Stone, 2002; Burnett et al., 
2011). This data suggests that AML in older adults is intrinsically more resistant 
to standard chemotherapy. Older patients have a greater incidence of secondary 
AML related to MDS or chemotherapy. They do have also greater incidence of 
unfavorable chromosomal abnormalities such as –5 and –7 and multi-drug 
resistant glucoprotein expression (Stone, 2002).  
Children with AML have more commonly favorable cytogenetic aberrations 
(Burnett and Eden, 1997; Lie et al., 2005). This feature together with impact of 
young age makes the prognosis for children relatively better than adults. CR is 
achieved in 70–90% of children with AML and the long-term survival rates 
reach up to 60% (Creutzig et al., 2001; Lie et al., 2005; Ravindranath, 2003). 
 
 
2.2.5 ALL treatment and clinical outcome 
The treatment of precursor B-cell and T-cell ALL both in children (Schmie-
gelow and Gustafsson, 2005) and adults (Bassan et al., 2004) are closely related 
and include four main components: 
1) induction therapy 
2) consolidation (re-induction or delayed intensification) therapy 
3) CNS prophylaxis 
4) maintenance therapy. 
 
The main components of the induction treatment are daily glucocorticoid 
(prednisolone or dexamethasone), weekly vincristine, and repeated doses of L-
aspariginase and/or anthracycline together with intrathecal methotrexate 
(MTX). The post-remission consolidation or re-intensification generally 
includes alkylating agents and/or epipodophyllotoxins, repeated doses of  
L-asparaginase and high-dose MTX with or without concurrent thiopurines. 
CNS-directed therapy consists of irradiation and/or high-dose MTX and/or Ara-
C with intrathecal MTX or triple therapy (MTX, Ara-C and glucocorticoids). 
The maintenance therapy consists of oral 6-mercaptopurine and oral or parental 
MTX at 1- to 2-weeks intervals and is given for two or three years. High-dose 





risk patients (Bassan et al., 2004; Schmiegelow and Gustafsson, 2005) due to 
the excess risk of transplant-related toxicity and mortality in standard-risk 
patients. 
The outcome of childhood ALL has improved dramatically since 1972 when 
the “Total therapy” concept – the combination of all known effective agents 
given during induction, intensification and maintenance of remission (Pinkel et 
al., 1972). With current risk-adapted therapy protocols, cure can be achieved in 
70–80% of children (Gustafsson et al., 2000; Schrappe et al., 2000). However, 
survival has improved mostly in children with good-risk features. Since these 
patients constitute almost 70% of all children, the improvement in prognosis in 
this group has strong impact on overall survival (OS) (Gustafsson et al., 2000). 
Children with high-risk ALL have inferior prognosis with five-year event-free 
survival of 50–70% (Schmiegelow and Gustafsson, 2005). In adult ALL, CR 
can be achieved close to 70–85% of patients, but more than half of those 
patients suffer a relapse and the cure rate is only about 20–40% of patients 
(Bassan et al., 2004). ALL patients with the t(9;22) translocation have the 
poorest survival with two-year survival rates <10–25%. The only curative 
option in this group of patients is allo-SCT (Bassan et al., 2004). The outcome 
of the t(9;22) ALL may improve by incorporating imatinib into treatment 
program (Delannoy et al., 2006; Wassmann et al., 2006). 
 
 
3. Minimal residual disease in acute leukemia 
It has been estimated that AL patients at diagnosis are burdened by approxi-
mately 1012 malignant cells and those who achieve mCR may carry between 0 
and 109 residual leukemia cells (Sievers and Radich, 2000). Minimal residual 
disease (MRD) is defined as persistence of leukemia cells at submicroscopic 
level in mCR patients. This means that in MRD patients the small number of 
leukemia cells still present in the body in an amount which is undetectable by 
conventional light microscopy. The final goal of detecting MRD is to obtain a 
more precise evaluation of the effectiveness of the treatment in order to: 
 design patient-adapted post-remission therapies which would reduce both 
the risk of relapse and over-treatment 
 predict impending relapses prior to clinical manifestations 
 make a better assessment of the quality of the stem cells harvested from 
auto-SCT 
 facilitate early therapeutic interventions such as donor lymphocyte 
infusions following allo-SCT. 
 
The detection of MRD is based on either immunophenotypical or molecular 
features that are present in leukemia cells, but not in normal haematopoietic 
cells (Campana and Pui, 1995). Molecular methods based on polymerase chain 




are able to detect one leukemia cell in 105 – 106 normal cells (van der Velden et 
al., 2003). However, this methodology can currently applied in only 20–30% of 
AML patients who have defined molecular targets, especially t(15;17), t(8;21) 
or inv(16) (Schoch et al., 2001; Yin and Grimwade, 2002). Even when patients 
with FLT3 gene length mutations and MLL gene internal tandem duplications 
are included, less than 50% of AML patients can be followed by PCR technique 
for MRD. In contrast to AML, MRD could be followed at least 80% of B-cell 
ALL and over 95% of T-cell ALL patients using patient-specific sequences of 
immunoglobulin or T-cell receptor rearrangements. However, the need to 
develop individual probes may cause limitations for the widespread use of 
MRD detection by PCR in ALL patients (Campana, 2003). 
Immunophenotyping by FCM is an attractive alternative for distinguishing 
small number of leukemia cells from normal counterparts. This method is based 
on aberrant, leukemia-associated immunophenotypes (LAIPs) that differ from 
normal antigen expression during haematopoiesis (Campana et al., 1990; Drach 
et al., 1992; San Miguel et al., 1999). FCM evaluates several antigens on one 
cell, gives quantitative results and can detect small abnormal cell population 
against a reactive background. The sensitivity of MRD detection by FCM 
depends on the number of analyzed cells, the type of phenotypic aberrations, 
and the combination of monoclonal MoAb reagents (Campana and Coustan-
Smith, 2004). By using live-gate strategy, in which at least 106 cells are 
acquired, a sensitivity of detection of one aberrant cell per 104 to 105 BM cells 




According to the BIOMED-1 Concerted Action report, 88% of AML, 85% of 
B-cell ALL and 100% of T-cell ALL patients display aberrant phenotypes at 
diagnosis, thus making MRD follow-up by FCM feasible (San Miguel et al., 
1999). FCM could be used for all AML patients via the application of a greater 
variety of fluorochromes and by improving the panel of antibodies, but a lower 
sensitivity due to the increased application of less aberrant LAIPs may limit this 
approach (Kern et al., 2003). Highly aberrant LAIPs in AML, which are not 
detectable in normal human adult BM at 0.01% level include: co-expression of 
CD34 together with CD2, CD7, CD14, CD56 or CD65 and triple-marker 
combination CD34+/CD15+/HLA-DR- (Macedo et al., 1995). The presence of 
highly aberrant LAIPs has been reported in 48% of childhood AML cases 
(Coustan-Smith et al., 2003). The most useful highly aberrant LAIPs in pre-
cursor T lymphoblastic leukemia (preT-ALL) are co-expression of T-cell 
markers CD3 and CD5 with TdT or CD34 and in precursor B lymphoblastic 
leukemia (preB-ALL) co-expression of myeloid-associated markers CD13, 
CD15, CD33, CD65, CD66c with CD19+/CD34+ leukemia cells (Campana and 
Coustan-Smith, 2004). The most frequently used marker combinations to detect 




Table 3. FCM marker combination for MRD detection in acute leukemias. 


























Abbreviations: My, myeloid marker 
 
 
3.2. Minimal residual disease as a predictor of prognosis 
Several studies have demonstrated that the level of MRD detected by either 
PCR or FCM based methods is a powerful predictor of prognosis in childhood 
ALL (Biondi et al., 2000; Björklund et al., 2003; Coustan-Smith et al., 2000; 
Willemse et al., 2002). Therefore MRD monitoring was incorporated into the 
NOPHO ALL-2000 protocol to form a basis for refined treatment stratification 
for the next protocol (Gustafsson et al., 2000). Less data is available on the 
prognostic significance of MRD evaluation in patients with AML. PCR based 
MRD monitoring is useful only in patients with t(15;17) where an increased 
level of t(15;17) transcripts are predictive for molecular and subsequent clinical 


























1) After induction MRD 
cut-off level 
4,5 x10–4 associated with 
outcome, but 
not significant  
2) After consolidation MRD 
cut-off level 3,5 x10–4 











4 different risk categories 
according to MRD levels: 
1) very low risk (<10–4), no 
relapse 
2) low risk (10–4 – 10–3), 
relapse rate 14% 
3) intermediate risk  
(10–3 – 10–2), relapse rate 
50% 
4) high risk (10–2), relapse 
rate 84% 
MRD levels are predictive 







29, 42 or 32 
1) After 1’st 
cycle (n=51) 
2) After 2’nd 
cycle (n=52) 
3) After 3’d 
cycle (n=39) 
1) After 1’st cycle MRD 
cut-off level 1%, RRR 6.1 
2) After 2’nd cycle MRD 
cut-off level 0.14%, RRR 
3.4 
3) After 3’d cycle MRD cut-
off level 0.11%, RRR 7.2 
MRD frequently correlated 




















1) LD as a continuous 
variable after induction; 
significantly related to RFS, 
but not OS. 
2) LD as a continuous 
variable after consolidation; 
significantly related to RFS 
and OS. 
Abbreviations: pts, patients; RFS, relapse-free survival; OS, overall survival; RRR, relative risk of 
relapse; NA, not available; Gr, group; LD log difference, the degree of reduction of malignant blasts 







The prognostic significance of MRD levels detected by FCM has only been 
investigated in two childhood AML studies. These studies demonstrate that the 
presence of MRD is related to a poor outcome (Coustan-Smith et al., 2003; 
Sievers et al., 2003). In adult AML, four groups have shown that MRD, 
especially above 0.1% of BM cells, detected either after induction treatment or 
at the end of post-remission chemotherapy, is highly predictive for subsequent 
relapse and shorter survival (Feller et al., 2004; Kern et al., 2004; San Miguel et 
al., 2001; Venditti et al., 2000). Results of these studies are summarized in 
Table 4. Unfortunately, there are still no guidelines on how to integrate the 
results of MRD analysis in treatment planning. In addition, the impact of MRD 
as a prognostic marker in AML patients treated by allo-SCT or auto-SCT has 
not yet been fully evaluated. 
During recent years European Leukemia Net has undertaken the task to 
harmonize MRD detection either by PCR or FCM, which should lead the way 
for development of common protocols for future co-operative studies (Cilloni et 
al., 2009; Béné and Kaeda, 2009). 
 
4. Late effects of acute leukemia therapy 
Even, if long-term remission is achieved, many patients need continuous 
medical attention due to complications imposed by leukemia or its treatment. 
The side effects of CNS irradiation include neurophysiologic deficits, endocrine 
disturbances and obesity. In children there is a risk of short stature. Patients who 
are cured from AL may have reduced fertility, develop cataract due SCT 
conditioning treatment with alkylating agents and total body irradiation, 
develop cardiomyopathy due to high doses of anthracyclines, develop osteo-
porosis or second cancer and may have reduced lung function (Schmiegelow 
and Gustafsson, 2005; Smith et al., 2004). The most common secondary 
malignancies are brain tumors, MDS or secondary AML usually associated with 
previous CNS irradiation and genotoxic chemotherapy (Schmiegelow and 
Gustafsson, 2005; Bassan et al., 2004). 
Current treatment protocols also induce a profound impairment of the 
immune system such as decreased immunoglobulin levels (Kristinsson et al., 
2001; Reid et al., 1981), loss of protective antibodies against measles, rubella 
and polioviruses (Nilsson et al., 2002; Smith et al., 1995) and persistent 
abnormalities in T-, B- and NK-cell subsets (Ek et al., 2005). Therefore, 
immunospression is a major side effect of anti-leukemia therapy. 
 
5. Dendritic cells 
Dendritic cells (DCs) play a central role in coordinating immune system 
response (Banchereau et al., 2000). DCs were first identified in 1868 by Paul 
Langerhans as ‚dendritic-shaped’ cells in the skin. DCs were ‚rediscovered’ by 
Steinman and colleagues in 1973 in mouse spleen (Steinman and Cohn, 1973). 
However, a major interest in DC research begun after the discovery of their 




DCs are uniquely able to induce primary immune responses and are the most 
potent antigen-presenting cells that recognize, process and present antigens to 
naïve, resting T-cells. Only DCs are able to stimulate naïve T-cells. In addition, 
DCs are the most effective cells that activate secondary T-cell responses and 
have the capacity to directly regulate B-cell responses as well (Banchereau et 
al., 2000). DCs develop from the BM haematopoietic progenitors under the 
control of soluble growth factors released from BM stroma cells and also direct 
cell-cell contact with BM stroma cells. DCs that leave BM are defined as DC 
precursors (preDCs) or immature DCs (iDCs) (Liu, 2001). 
Three subtypes of HLA-DR+ preDCs have been described in human blood. 
The first are monocytes, which depending on cytokines, can differentiate into 
iDCs or macrophages (Gordon and Taylor, 2005). Two other preDCs subtypes 
lack the expression of lineage markers such as CD3, CD14, CD19, CD20 and 
CD56, but express high levels of HLA-DR and either high levels of CD11c, 
which is integrin- or CD123 the receptor for Interleukin (IL)-3. PreDCs, 
which express high levels of CD11c and do not express CD123, are defined as 
myeloid DCs (mDCs) and they belong to the same lineage as monocyte-derived 
DCs (O’Doherty et al., 1994; Sallusto and Lanzavecchia, 1994). PreDCs that 
express high levels of CD123 and low levels of CD11c are defined as lymphoid 
or plasmacytoid DCs (pDCs) (Grouard et al., 1997; Olweus et al., 1997). It has 
been suggested that both DC subtypes can drive either Th-1 or Th-2 types of 
response or promote antigen-specific tolerance depending on the stage of 
differentiation and activation (Langenkamp et al., 2000; Mahnke et al., 2002). 
At present, mDCs and pDCs are thought to preferentially recognize different 
antigens or pathogens. In response to viruses (Kadowaki et al., 2000) and to 
bacterial DNA rich in unmethylated CpG motifs (Hartmann et al., 1999; Hemmi 
et al., 2000), pDCs produce large amounts of IFN-. Myeloid DCs produce 
large amounts of pro-inflammatory cytokines such as TNF-, IL-6 and IL-12 in 
response to glycoproteins from gram-positive bacteria (Lien et al., 1999) and 
lipoproteins from gram-negative bacteria (Poltorak et al., 1998). Furthermore, 
DCs are pivotal for the induction and maintenance of anti-tumor immune 
responses. Accumulating data indicates severe deficiencies in DC numbers and 
functions in cancer patients (Gabrilovich, 2004). Defects in DC function have 
been demonstrated in AML (Mohty et al., 2001), chronic myeloid leukemia 
(Mohty et al., 2002), hairy cell leukemia (Bourguin-Plonquet et al., 2002) and 
myeloma (Brimmes et al., 2006) and in patients with solid tumors (Gabrilovich, 
2004). Two studies have demonstrated severe deficiency of pDCs and mDCs in 
peripheral blood of children with preB-ALL, but not with preT-ALL at 
diagnosis (Maecker et al. 2006; Mami et al., 2004). Collectively this data 
indicate that the impairment of the DC system may be one of the key factors in 
the late immune dysfunction observed in patients with ALL and may even have 
a role in tumor control. Therefore, there is an obvious need to study DCs 
regeneration pattern during acute leukemia therapy in different patients’ 




AIMS OF THE STUDY 
The major aims of the thesis were to evaluate the usefulness of FCM in 
haematological malignancies. More specifically, the aims were: 
 To identify the value of FCM in lymphoma diagnosis in FNA material 
(Paper I) 
 To determine the prognostic relevance of the MRD in young adult AML 
patients detected by FCM in relation to SCT (Paper II) 
 To determine the DCs levels at diagnosis and their pattern of regeneration 
evaluated by FCM in BM of children treated for ALL according to 





































MATERIALS AND METHODS 
1. Patients 
This study included in total 526 patients (256 male and 270 female), ranging in 
age from 2 months to 94 years, who were investigated or treated in Karolinska 
Hospital, Astrid Lindgren Children’s Hospital in Stockholm and at University 
Children’s Hospital in Uppsala, Sweden during 1994–2005. 
The patient group of FCM study on FNA diagnosis of lymphoma (Paper I) 
consisted of 396 patients (187 male and 209 female), in age 4–94 years, median 
60 years. 
The patient group of MRD study in AML by FCM (Paper II) included 45 
patients (23 males and 22 females) in age range 19–60 years, median 47 years. 
The patient group of DCs study in ALL treated according to NOPHO ALL-
200 protocol (Paper III) was formed of 76 children (42 boys, 34 girls). Median 
age at diagnosis was six years (1–17 years). 
Nine children without haematological diseases formed a small hospital 
control (HC) group for establishing reference levels for DC subsets in the BM 
(Paper III). HC group consisted of four boys and five girls with median age four 
years (range 2 months – 13 years). Seven children had reactive BM, one had 





The study was conducted according to the Helsinki Declaration and was 
approved by the local ethics committee. 
 
 
1.2. Patients’ selection and definition of diagnosis 
Patients’ selection to study FCM usfulness on FNA diagnosis of lymphoma 
(Paper I) 
To study the value of FCM in diagnosis of lymphoma we prospectively 
included samples from 3038 patients with suspect lymphoma referred to the 
Division of Clinical Cytology, Karolinska Hospital, Stockholm, Sweden, for 
FNA between May 1999 and October 2001. From a total of 3038 FNAs 
performed during that period, IC was performed in 1088 samples. Samples with 
cell concentrations of less than 5×105 cells/ml, with large cells suggesting 
Hodgkin’s lymphoma, metastasis of other tumors and from lymph node smaller 
than 1 cm in diameter from children were excluded from the study. In total 424 
FNA samples obtained from 396 patients were analyzed by FCM. Of 396 





patients had FNA twice and one patient had FNA three times taken. In these 
patients, FNA were performed at different lesions and/or different occasions. Of 
the 424 FNAs studied by FCM, 352 samples (83%) were obtained from lymph 
nodes and 72 (17%) from extranodal tissue (17 from the parotis, 14 from 
subcutaneous tissue, nine from breast tissue, seven from the orbita, seven from 
the tonsil, five from the spleen, four from skin lesions, three from sub-
mandibular glands, two from kidney tumors, two from the thyreoidea, one from 
the gum and one from the liver). Reactive hyperplasia of lymphoid tissue (RH) 
was diagnosed in 172 samples from 164 patients and NHL in 239 samples from 
228 patients. Primary lymphoma was diagnosed in 141 patients. Relapse of 
lymphoma was found in 97 samples from 87 patients. Thirteen samples from 13 
patients (seven cases of Hodgkin’s lymphoma, two cases of angioimmuno-
blastic lymphadenopathy, two cases of dermatopathic lymphadenopathy, one 
case of lateral neck cyst and one case of seroma) were excluded from data 
analysis. 
The initial diagnosis on FNA was made by two cytopathologist. Cytologic 
and immunologic criteria for the classification of NHL and RH were based on 
the Revised European-American Classification of Lymphoid Neoplasms (Harris 
et al., 1994). Primary lymphoma was defined as a previously undiagnosed 
lymphoma in which the FNA was the primary diagnostic test. Recurrent 
lymphoma was defined as one in which the diagnosis of lymphoma had been 
made by a previous biopsy. For the purpose of the study, the same observers 
reviewed all samples with discrepant diagnoses. For histopathologic diagnosis, 
Revised European-American Classification of Lymphoid Neoplasms and WHO 
classifications were used (Jaffe, 2001). The final diagnosis was recorded 
according to histopathologic examination or by cytology report if the biopsy 
was not performed. 
 
 
Patients’ selection to study MRD by FCM in young adult AML (Paper II) 
To study the value of FCM in MRD detection in patients with AML we 
analyzed 62 young adults in age 19–60 years in whom non-promyelocytic AML 
was diagnosed between July 1994 and June 2001 at Karolinska University 
Hospital Solna, (Stockholm, Sweden). mCR was achieved in 53 of 62 patients 
(85%). Eight patients were excluded due to: 
 uninformative phenotypes (n=3), 
 lack of sufficient clinical data (n=2) 
 lack of sufficient FCM information (n=3). 
 
Follow-up MRD information was available in 45 mCR patients. At diagnosis 
the following data was recorded {median (range)}: percentage of BM blasts 
71% (34–96%), total WBC count 23 (0.5–237) x109/L, hemoglobin (Hb) level 




time of surviving patients was five years (range 2–9 years). Most of the MRD 
data was collected during 1994 – 2000 and integrated in the European 
BIOMED-1 Concerted Action (BMH-CMT 94–1675) (San Miguel et al., 1999). 
The treating physicians were not aware of the MRD results. 
The AML diagnosis was based on morphology and cytochemistry following 
the FAB classification (Bennett et al., 1976): three M0, 10 M1, nine M2, 11 
M4, 10 M5, one M6, and one case of acute undifferentiated leukemia (AUL). 
All samples were reviewed and reclassified according to the WHO classification 
(Jaffe, 2001): three AML with recurrent genetic abnormalities {one AML with 
t(8;21)(q22;q22), one AML with inv(16)(p13q22) or t(16;16)(p13;q22) and one 
AML with 11q23 (MLL) abnormality}, four therapy related AML, 38 AML not 
otherwise categorized (four minimally differentiated AML, 10 AML without 
maturation, six AML with maturation, eight acute myelomonocytic leukemias, 
eight acute monoblastic and monocytic leukemias, one acute erythroid 
leukemia, and one bilineal acute leukemia). 
Morphological CR was defined as less than 5% blasts without detectable 
Auer rods in BM samples displaying ≥20% cellularity with the maturation of all 
haematopoietic cell lines in the BM aspirate. 
 
 
Patients’ selection to study DCs levels in BM in childhood ALL (Paper III) 
The study on DCs levels in BM in childhood ALL was based on 111 children 
over one year old, who were diagnosed with de novo ALL at Astrid Lindgren 
Children’s Hospital in Stockholm and at University Children’s Hospital in 
Uppsala, Sweden between February 2002 and October 2005. Of these, 76 
patients (42 boys, 34 girls) fulfilled the following inclusion criteria: 
 treatment according to NOPHO ALL-2000 protocol (Table 5; Figure 3); 
 included in NOPHO ALL-2000 MRD study;  
 DCs levels measured at least twice during therapy. 
 
The ALL diagnosis was based on WHO classification. Sixty-seven children had 
preB-ALL and nine had preT-ALL (Anon, 1998; Jaffe, 2001). 
In the HC group, BM cellularity and cell-lineage maturation were normal for 





Table 5. Distribution of patients within NOPHO-ALL 2000 protocol for ALL >1 years. 
Standard- and intermediate-risk group (N = 54) 
ALL patients without unfavorable features: 
WBC < 50.0 x 109/l and B-precursor ALL and no CNS – leukemia and no testis – 










N = 24 1)  B-precursor ALL and 
2)  Age 1 to < 10 years of age and  
3)  WBC<10.0 x 109/l and 
4)  No unfavorable features and 




(Protocol II)  
N = 30 1)  B-precursor ALL and 
2)  Age 1 to < 10 years and WBC 10.1 to < 50.0 x 109/l or 
3)  Age > 10 years and WBC < 50.0 x 109/l and 
4)  No unfavorable features and 
5)  Good response to initial therapy 
High-risk group: (N =22) 
ALL patients with unfavorable features: 
WBC >50.1 x 109/l and T-cell ALL and/or CNS – leukemia and/or testis – leukemia  
and/or 11q23, t(9;22), t(1;19) and/or hypodiploidy 










N = 8 1)  WBC 50–200.0 x 109/l and age < 5 years or WBC 50–100.0 
x109/l and age > 5 years and/or 
2)  T cell ALL without mediastinal mass or T cell ALL with 
mediastinal mass and age < 5 years and/or 
3)  11q23/MLL-rearrangements and age < 10 years (optional) 
and/or 
4)  CNS involvement and age < 5 years and/or 
5)  No t(9;22)(q34;q11)/BCR-ABL fusion and 
6)   Chromosomal G-banding analyses show 34–<45  
      chromosomes or DNA-index < 0.95 
7)  Patients on Intermediate Intensity therapy and MRD > 10–3 





N = 8 Age > 5 years at diagnosis and 
1) T cell ALL and a mediastinal mass and/or 
2) WBC 100–200.0 x109/l and/or 
3) CNS-involvement at diagnosis (to receive cranial radio-






N = 6 1) Very slow response, defined as M3 status (>25% 
lymphoblasts) in the BM on day 29 and/or 
2) 11q23/MLL-rearrangements and age > 10 years (age 2–9 
years: BMT optional) and/or 
3) t(9;22)(q34;q11)/BCR-ABL fusion and/or 
4) Hyperhaploid karyotype with modal number <34 and/or  




*Response to therapy is defined as follows: 
Good response to initial therapy: 
A bone marrow on day 15 with < 25% blasts (= M1 or M2 BM) in a non-
aplastic bone marrow 
A bone marrow on day 29 with < 5% blasts (= M1 BM) in a non-aplastic bone 
marrow 
 
Poor response to initial therapy: 
A bone marrow on day 15 with > 25 % blasts (=M3 BM) in a non-aplastic bone 
marrow 
A bone marrow on day 29 with > 25% (= M3 BM) or 5–25 % (=M2) in a non-
aplastic bone marrow 
 
 
Figure 3. Dendritic cell (DC) and minimal residual disease (MRD) measurement during 
NOPHO ALL-2000 treatment protocol. 
 
 
Patients were stratified into different therapy groups according to the risk 
criteria present at diagnosis (see Table 5). Time-points of DC detection and 
MRD tests are indicated by arrows in an overview of NOPHO ALL-2000 









2. FNA cytology 
All FNA biopsies were performed by an experienced cytopathologist with a 
needle 0.4 to 0.6 mm in diameter, according to the procedure described by 
Zajicek (Zajicek, 1974). Deep-located lesions were aspirated under ultrasound 
control. One part of the aspirate was used to prepare smears, which were air-
dried or methanol fixed and stained by May-Grünwald-Giemsa or Papanicolau 
technique, respectively. Additional air-dried smears were fixed in freshly 
prepared 4% buffered formalin and used to study proliferation. The other part of 
the aspirate was suspended in phosphate buffered saline (PBS). Cell viability by 
trypan blue exclusions and cell concentration in suspensions was assessed 
immediately after the FNA procedure. One half of the cell suspension was used 
for FCM study and from the other half cytospin preparations in a cytocentrifuge 




IC on cytospins was performed in 60% (253/424) of samples and during the 
first year of study in 70% (73/103) of samples. IC on cytospins was not 
performed in all cases because after the first year of study we found an excellent 
correlation between IC and FCM in low-grade B-cell NHLs (LG-NHL) and RH. 
Therefore, immunophenotyping was done subsequently only by FCM in most 
cases of RH and of recurrent LG-NHL. 
A three-step alkaline phosphate anti-alkaline phosphatase method was 
employed (using alkalin phosphatase anti-alkaline phosphatase reagents from 
DAKO, Glostrup, Denmark). Single stainings were performed with the 
following monoclonal antibodies: anti-kappa (clone A8B5, dilution 1:10), 
CD10 (clone SS2/36, dilution 1:20), CD20 (clone L26, dilution 1:50) and Bcl-2 
(clone 124, dilution 1:40) from DAKO. Anti-lambda (clone 1–155–2, dilution 
1:50), CD3 (clone SK7, dilution 1:40) and CD5 (clone L1F12, dilution 1:40 




Lymph node excision (n=91) or biopsies from extranodal tissues (n=33) were 
performed in 124 of 396 patients. Tissue specimens were fixed in formalin or 
B5 fixative and routinely stained for morphological examination only with 
hematoxylin and eosin, Gimesa, periodic acid-Schiff and Gordon-Sweet 
methods. Immunophenotyping was performed by FCM on lymph node cell 






4. Cytogentics of AML 
Karyotypes were available in 43 patients and were classified into three groups 
essentially in accordance with Grimwade et al (Grimwade et al., 1998). 
 two patients with t(8;21) and inv(16) formed a favorable group,  
 five patients with 5q-, near-tetraploid and complex aberrant karyotypes 
(i.e. ≥3 clonal chromosome aberrations) were considered as an unfavo-
rable group, 
 36 patients with trisomy 8, t(9;22), other aberrations and normal karyo-
types belonged to an intermediate prognostic group. 
 
 
5. Treatment and outcome 
5.1. Young adult AML 
Most patients with AML (n=42) received induction therapy with idarubicin 
(10 mg/m2 infusion d 1–3), Ara-C (1000 mg/m2 infusion twice daily d 1–4), and 
etoposide (100 mg/m2 infusion d 1–5). CR patients were given 2 cycles of 
consolidation therapy consisting of idarubicin (10 mg/m2 infusion d 1–2), Ara-C 
(1000 mg/m2 infusion twice daily d 1–3), and etoposide (100mg/m2 infusion d 
1–4). The third cycle of consolidation consisted of Ara-C (1000 mg/m2 infusion 
twice daily d 1–6). One patient with AUL was given ABCDV that consisted of 
Ara-C, betamethasone, cyclophosphamide, doxorubicin and vincristine and 2 
patients were treated with mitoxantrone, etoposide and Ara-C (Björkholm et al., 
1995). Allo-SCT in the first CR was performed in 16 patients. Auto-SCT as 
consolidation in the first CR was performed in 15 patients: CR patients with no 
sibling donor received total body irradiation and high-dose Ara-C followed by 
auto-SCT (Rohatiner et al., 1998; Smith et al., 2004). Thirty patients achieved 
mCR after one induction course, 12 after two and three patients after three 
courses. 
MRD levels were determined at two time-points: 
 (1) – at first mCR after induction treatment, 
 (2) – at the end of post-remission chemotherapy or before allo-SCT or 
auto-SCT. 
 
A relapse was diagnosed in 17/45 mCR patients (38%) at median 10 months 
after mCR (range 2–20 months). One patient had MDS. RFS for patients who 
had achieved CR was determined as the duration from the date of the first CR to 
censoring point, first relapse or death due to any cause. The median RFS time 
was 36 months (range 2–105 months). OS was measured from the date of 
diagnosis to death or the censoring point. Twenty patients (44%) had died and 
the median OS was 42 months (range 4–107 months). The cause of death was 
AML relapse in 13 patients, MDS in one patient, allo-SCT related compli-




5.2. Childhood ALL 
Children with ALL were divided into two main groups based on the presence or 
absence of unfavorable features and stratified into five protocols according to 
NOPHO ALL-2000 (Table5; Figure 3). Detailed therapy protocols have been 
published elsewhere (Gustafsson et al., 2000; Schmiegelow and Gustafsson, 
2005). CR was achieved in 75 children (98.7%). Two patients suffered systemic 
ALL relapse and one patients isolated central nervous system relapse. Three 
patients had died due to relapse or refractory disease. All patients without 
unfavorable features who were stratified into Standard Intensive therapy (SI) 
and Intermediate Intensive therapy (II) had good response to initial therapy and 
therefore were not up-graded into more intensive protocols. 
Precursor B-ALL patients without unfavorable features who were stratified 
into Protocol SI (preB-ALL [SI]) and Protocol II (preB-ALL [II]) formed 
standard-risk (SR) group. DC subsets were evaluated in SR group at eight time-
points: diagnosis, treatment days 15 (week 2), 29 (week 4), 50 (week 7), 106 
(week 15), at the beginning of Maintenance (I) (week 130), at the end of 
treatment protocol and six months after the end of chemotherapy. 
Precursor B-ALL patients with unfavorable features formed preB-ALL high-
risk group (preB-ALL HR). Patients with preB-ALL HR and preT-ALL formed 
together high-risk group (HR group). DC subsets were evaluated in HR group at 
seven time-points: diagnosis, treatment days 15 (week 2), 29 (week 4), 50 
(week 7), 106 (week 15), at the beginning of Delayed Intensification (week 28) 
and the end of treatment protocol. 
MRD levels were determined at the same time points as DC levels. 
 
 
6. Flow cytometry 
Sample preparations 
FNA aspirates were collected in tubes containing PBS and were processed 
within 2h. BM samples were collected in heparin anticoagulant tubes, directly 
diluted 1:1 (vol/vol) with 0.9% NaCl and maintained at room temperature (RT). 
All samples were processed within 24h. A “stain and then lyse/wash” technique 
was used: 100 l of BM cell suspension with at least 1×106 nucleated cells were 
incubated for 10–15 min in RT, in the dark with saturating amounts of triple or 
quadruple combinations of moAb. After incubation with moAb, 2 ml of FACS 
lysing solution (BD, diluted 1/10 in distilled water) were added and samples 
were incubated for another 5 min at RT, in the dark. After erythrocytes lysis, the 
cells were centrifuged for 5 min with 500 g, washed in 2 ml PBS and suspended 
in 0.5 ml of PBS. In moAb combinations including cytoplasmic or nuclear 
antigens the staining for surface markers was performed as described above and 
was followed by a fixation and permeabilization of cell membrane with 800 l 




distilled water for 30 min or with 100 l Intrastain solution A from DAKO for 
15 min. After OPM or Intrastain fixation the cells were centrifuged for 5 min, 
500 g and washed with 2 ml PBS. A further incubation with moAb to 
cytoplasmic or nuclear antigens followed for 30 min in OPM prepared samples 
and 15 min in Intrastain-processed samples together with 100 l of Intrastain 
solution B. Finally, the cells were washed in 2 ml PBS and suspended in 0.5 ml 
PBS. Both intracellular procedures gave equal results in detecting nuclear TdT 
or cytoplasmic CD3. In all cases, isotype-matched immunoglobulins with no 
reactivity against BM cells were used as negative controls. 
 
 
Data acquisition and analysis 
Data acquisition was performed using FACScan or FACS-Calibur flow 
cytometer, equipped with Lysis II or Cell Quest software programs from BD 
(Franklin Lakes, NJ, USA). Light scatter characteristics and autofluoresence 
levels of normal peripheral blood lymphocytes were used as reference values 
for instrument settings. Instrument setup and calibration were performed with 
CaliFlow beads (Spherotech Onc., Libertyville, IL, USA). 
On average 8 874 non-gated events (544–10 000) were acquired per tube in 
immunophenotyping of FNA material. Data analysis was performed with 
CellQuest (tubes 1–3) and Paint-a-Gate (BD, tube 4; Figure 4) software 
programs. Bcl-2 expression was evaluated by mean fluorescence intensity 
(MFI) for separately gated CD3+ T-cells, CD19+ B-cells and CD10+/CD19+ 
B-cells. Bcl-2 MFI for normal T-cells present in the samples remained the same 
throughout the study (MFI 93.6  31.8, median 89), which confirmed stability 
of the measurements allowing comparison of Bcl-2 expression in various NHL 
categories. 
FCM criteria for phenotypic classification of LG-NHL and RH are presented 
in Table 6. Only CLL, MCL and FL displayed characteristic immunopheno-
types. FCM differentiation between immunocytoma/lymphoplasmocytic 
lymphoma (IC/LPL) and extranodal marginal zone B-cell lymphoma of 
mucosa-associated lymphoid tissue type/nodal marginal zone lymphoma 
(MALT/NMZL) was not possible, but localization and clinical data allowed 
correct diagnosis in most cases. Scatter characteristics was one of the important 
features in diagnosis of HG-NHL. Monoclonality was defined as a kappa/ 









Figure 4. Illustration of FCM detection of antigen expression in lymphocyte subsets. 
 
Expression of various markers was investigated in a “lymphocyte gate”, set on a 
forward scatter (FSC) versus side scatter (SSC) plot or in B or T cells gated on 
SSC and CD19 or CD7 expression, respectively. a,b: The first tube was 
composed to investigate Ig light-chain restriction in separately gated CD19+ B-
cells (a) and to determine a fraction of CD5+ B-cells (b). c: The second tube 
was designed to detect CD10 and/or CD23+ B-cells. d: The third tube allowed 
to determine CD4/CD8 ratio and to detect abnormal T-cell populations. e,f: The 
fourth tube was used to evaluate Bcl-2 expression in separately gated T cells, B 
cells and CD10+ B-cells. Plot a shows polyclonal expression of kappa and 
lambda in RH after CD19/SSC gating; kappa-positive B cells are shown in red, 
and lambda-positive B cells in green. Plot b shows lymphocyte subpopulations 
which were investigated in the lymphocyte gate set on FSC and SSC in the 
same sample; Normal CD19+/CD5- B-cells are shown in violet, normal 
CD5+/CD19- T-cells in blue and CD19/CD5 double positive cells in cyan. Plot 
c illustrates a Follicular lymphoma case in which malignant B-cells are 
CD10+/CD23- (red); CD10/CD23 double positive cells as cyan. Plot d shows 
the determination of CD4/CD8 ratio in reactive T cells after CD7/SSC gating; 
CD4+ T-cells are shown in green and CD8+ T-cells in blue. Plot e illustrates the 
Bcl-2 analysis in separately gated CD3+ T-cells (blue) and CD19+ B-cells (red) 
in Follicular lymphoma sample. Plot f shows that CD19+ B-cells in the same 
sample also express CD10 (red) and this population has a higher expression of 
Bcl-2 than do T-cells (blue). APC, allophycocyanin; Cy5, indodicarbocyanine; 




Table 6. FCM immunophenotypic criteria for classification of B-Cell NHL and RH 
(Jaffe, 2001). 
Diagnosis CD19 CD5 CD23 CD20 CD10 K/L 
CLL + + + +(weak) – Clonal 
FL + – – + + Clonal 
IC/LPL + – – + – Clonal 
MALT/NMZL + – – + – Clonal 
MCL + + – + – Clonal 
HG-NHL + – –/+ +/– +/– Clonal 
RH + – –/+ +/– –/+ Polyclonal 
Abbreviations: CLL, chronic lymphocytic leukemia; FL, follicular lymphoma, HG-NHL, high-
grade B-cell non-Hodgkin’s lymphoma; IC/LPL, immunocytoma/lymphoplasmocytic 
lymphoma;K/L, kappa/lambda light-chain ratio; MALT/NMZL, extranodal marginal zone B-cell 
lymphoma of mucosa-associated lymphoid tissue type/nodal marginal zone lymphoma; MCL, 
mantle cell lymphoma; RH, reactive hyperplasia. 
 
 
At AML diagnosis a total of 15 x 103 non-gated events were acquired. Based on 
immunophenotypes at diagnosis, phenotypic abnormalities were defined and 
used in follow-up samples. Applied three-color moAb (Table 3) combinations 
were tested in normal or reactive BM samples for sensitivity in detecting LAIPs 
in the current study or by other groups (Venditti et al., 2000; Feller et al., 2004; 
Macedo et al., 1995; Kern et al., 2003). At follow-up, at least 30 000 cells were 
analyzed in each tube. Live-gate analysis was used in five patient’s follow-up 
samples. A total of 100 000–500 000 cells were analyzed in allowing sensitivity 
of at least 0.015%. Data-analysis was performed using Paint-a-Gate Pro (BD) 
software (Figure 5). In most cases CD34/SSC or CD117/SSC gates were 
applied. Detectable MRD was defined as a distinct cluster of 15–20 dots. 
Sensitivity levels were determined as: 
 0.1% if 30 000 events were acquired, 
 0.05% if 30 000 events were acquired in cases with highly aberrant LAIP 
as co-expression of CD34 and CD7, CD14, CD56 or CD65 and 
CD34+/CD15+/HLA-DR-, 















Figure 5. Illustration of sequential flow cytometry MRD analyses after induction 
(MRD1), at the end of post-remission treatment (MRD2) and before overt relapse in an 
AML patient who eventually relapsed. 
 
The three-color moAb combination of CD34 FITC/CD11b PE/HLA-DR PerCP 
was used in the follow-up samples to detect MRD. The aberrant phenotype 
relied on over-expression of CD11b and lower than normal expression of HLA-
DR in CD34+ cells. The positivity for CD11b and HLA-DR was similar at 
diagnosis and at incipient relapse (illustrated in the right upper and lower plots). 
The left upper plot shows CD34 positivity at diagnosis (CD34 PE/SSC plot) and 
left lower plot gating strategy during follow-up (CD34 FITC/SSC plot). The 
frequencies of CD34+/CD11b+/HLA-DRdim triple positive cells at indicated 
time-points expressed as percentages of total BM events are shown in upper and 
lower middle plots. 
 
DC frequency was evaluated by Lineage cocktail 1 (lin)-FITC/CD123-
PE/HLA-DR-PerCP/CD11c-APC (BD, San Jose, CA, USA), see Figure 6. 
Plasmacytoid DC immunophenotype was characterized as lin-/HLA-DR+/ 
CD123+ and myeloid DC as lin-/HLA-DR+/ CD11c+ (Figure 6). The lin 




average, 150 000 non-gated events were acquired. A DC subset was detected 
when a distinct cluster of at least 10 dots was found. Data-analysis was 
performed using Paint-a-Gate Pro (BD) software (Figure 6).  
MRD was analyzed by four-color flow cytometry as described in previous 
publication (Björklund et al., 2003). MRD was defined as a presence of a 
distinct cluster of cells with LAIP in BM.  
 
 
Figure 6. Detection of dendritic cell (DC) subsets. 
 
 
Illustration of DC subset analysis in bone marrow sample from a hospital 
control group patient. 100 l of sample was incubated with following anti-
bodies: 20 l of the Lineage cocktail 1 FITC (cat nr. 340546, contains CD3, 
CD14, CD16, CD19, CD20 and CD56), 10l CD123 PE (cat nr. 340545), 10l 
anti-HLA-DR PerCP (cat nr. 347402) and 5 l CD11c APC (cat nr. 3337402). 
All antibodies were obtained from Becton & Dickinson Biosciences (BD), 
Franklin Lakes, NJ, USA. 
Upper left plot (a) shows the gating strategy of Lin cocktail negative and 
HLA-DR strongly positive cells. Middle upper plot (b) shows localization of 
DCs on forward scatter (FSC)/ side scatter (SSC) plot. Plasmacytoid DCs 
(pDCs) were identified by high levels of CD123 and were negative for CD11c 
{red dots, lower left (d) and right (f) plot}. Myeloid DCs (mDCs) expressed 





(f) plot}. Plasmacytoid DCs were slightly smaller than mDCs {red and green 
dots, respectively, upper right plot (c)}. DC subsets were quantified as 
percentage of total BM events. Analysis was performed by Paint-A-Gate 
software (BD).  
Abbreviations: FITC, flourescein isothiocyanate; PE, R-phycoerythrin; 
PerCP, peridinin chlorophyll protein; APC, allophycocyanin. 
The diagnostic flow cytometry panel is listed in Table 7. 
 
 
7. Statistical analysis 
Descriptive statistics, analysis of variance and Dunnett’s T3 post hoc tests were 
used in SPSS 9.0 (SPSS, Inc., Chicago, IL, USA) to analyze differences in 
frequencies of B and T cells, PI and Bcl-2 expression across NHL categories .  
Dichotomous variables were compared between different groups using the 2 
test and continuous variables by Student’s t test. Spearman rank correlation (r) 
was used to investigate correlations between continuous variables. RFS and OS 
were estimated according to the Kaplan-Meier method and differences between 
groups were analyzed using the log-rank test. The Cox proportional hazard 
method was used for multivariate analysis. 
Non-parametric Mann-Whitney test was used for comparison of DC subset 
levels at different time-points. Spearman rank correlation (r) was used to 
investigate correlations between continuous variables and Wilcoxon’s rank sum 
test for comparison of DC levels in different patient groups. P-values <0.05 
were considered significant. All reported P-values are two-sided. All calcu-





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1. Diagnostic value of FCM in NHL diagnosis  
in FNA aspirates (Paper I) 
1.1. Accuracy of FCM in diagnosis of NHL 
1.1.1. Low-grade NHL 
Our FCM panel was very efficient in detecting LG-NHL. The LG-NHL cate-
gories (FL, CLL, IC/LPL, MALT/NMZL, MCL, B-NHL-UN) were correctly 
diagnosed in 95% (177 of 186) of cases (Table 8).  
 
Table 8. Accuracy of primary and recurrent lymphoma diagnoses 
Cytopathologic 
diagnosis 
Cases (n) FCM concordancea Histopathologic 
confirmation 
Primary    
FL 47 45/47 (96%) 28/47 (60%) 
CLL 26 26/26 (100%) 10/26 (38%) 
IC/LPL 8 8/8 (100%) 2/8 (25%) 
MALT/NMZL 15 15/15 (100%) 2/15 (13%) 
MCL 6 4/6 (67%) 4/6 (67%) 
HG-NHL 29 22/29 (76%) 10/29 (34%) 
T-NHL 7 3/7 (43%) 5/7 (71%) 
B-NHL-UN 4 0/4 0/4 (0%) 
Total 142 123/142 (87%) 61/142 (43%) 
Recurrent    
FL 33 33/33 (100%)  
CLL 32 32/32 (100%)  
IC/LPL 2 2/2 (100%)  
MALT/NMZL 8 7/8 (88%)  
MCL 5 5/5 (100%)  
HG-NHL 7 6/7 (86%)  
T-NHL 10 6/10 (60%)  
Total 97 91/97 (94%)  
Abbreviations: B-NHL-UN, B-cell non-Hodgkin’s lymphoma, unspecified; CLL, chronic 
lymphocytic leukemia; FCM, flow cytometry; FL, follicular lymphoma; HG-NHL, high-grade B-
cell non-Hodgkin’s lymphoma; IC/LPL, immunocytoma/lymphoplasmocytic lymphoma; 
MALT/NMZL, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue 
type/nodal marginal zone lymphoma; MCL, mantle cell lymphoma; T-NHL, T-cell non-
Hodgkin’s lymphoma. 
a Cases in which the FCM results was in concordance with the final diagnosis. In case of FL, CLL 
and MCL characteristic pathologic immunophenotype was detected by FCM. In case of IC/LPL, 
MALT/NMZL and HG-NHL pathologic monoclonal B-cell population was detected. In T-NHL 
an aberrant phenotype within the T-cell population was found. 
In four cases lymphoma subclassification was not possible (B-NHL-UN) and was therefore 




In total, histopathologic examination was available in 46% (86 of 186) of  
LG-NHL cases. Cytologic diagnosis was concordant with histopathology in all 
cases. Eight samples were diagnosed by FCM as unspecified LG-NHL. In two 
of these cases histopathology confirmed CD10- FL based on morphologic 
observations and Bcl-6 expression. Another two samples appeared to be MCL. 
On review of FCM plots of both cases, we found a low level of CD5 expression 
that was not correctly evaluated during initial analysis. Cyclin D1+ MCL was 
confirmed in one case by lymph node histopathology and in the second case by 
BM examination. LG-NHL subclassification was not possible in four patients. 
Cytologic findings suggested diagnosis of FL because of a predominance of 
small to medium-sized centrocyte-like cells. However, theses lymphomas were 
CD10- and in three studied cases FISH analysis did not show t(14;18), t(11;14) 
or t(11;18). However, FISH analysis showed extra copies of chromosomes 11, 
14 and 18 in one case and trisomy 18 in one case. In one patient genetic studies 
were not available due to lack of material. In these four patients biopsy for 
histologic examination was not performed because patients were older than 76 
years and the biopsy was considered uninformative regarding treatment 
decisions. In one sample of recurrent MALT/NMZL, FCM did not show a 
monoclonal B-cell population. This sample was obtained from soft tissue and 
had a very low cell count; on average only 1500 events were registered per tube. 
 
 
1.1.2. High-grade NHL 
HG-NHL was diagnosed in 36 FNA samples from 35 patients (31 cases of 
DLBCL, two of Burkitt-like lymphoma, two of TCRBCL and one of anaplastic 
B-cell lymphoma). Anaplastic and both TCRBCL diagnoses were confirmed by 
tissue biopsy. Immunoglobulin (Ig) heavy-chain gene rearrangement analysis 
was done in one case of TCRBCL, which showed clonal Ig rearrangement. 
In 78% (28 of 36 samples) FCM suggested a diagnosis of lymphoma. From 
these 28 samples Ig light-chain restriction was detected in 22 samples of 
DLBCL and two of Burkitt-like NHL. In four samples malignant B-cells did not 
express surface Ig (sIg). In eight samples FCM was not able to diagnose 
lymphoma: one case of anaplastic B-cell lymphoma, two cases of TCRBCL and 
five cases of DLBCL. In these samples FCM analysis showed a dominant 




T-NHL was found in 17 patients. T-NHL diagnosis was confirmed in 13 cases 
by tissue histopathology. T-cell receptor gene rearrangement analysis was done 
in four primary and three recurrent cases. In 53% of T-NHL cases (three of 
seven primary lymphomas and six of 10 relapsed lymphomas) FCM showed 




CD4/CD8 ratio (11–23) in three samples, CD4+CD7– population in three 
samples, CD4/CD8 double negative in one sample or double positive population 
in one sample. T-cell precursor leukemia/lymphoma diagnosis was confirmed 
by an additional study that showed expression of terminal TdT. In one sample 
FNA and cytology showed reactive changes in an enlarged lymph node. 
However, in this case CD4/CD8 ratio was 17.7 and recurrence of T-NHL was 
confirmed by T-cell receptor gene rearrangement analysis. 
 
 
1.2. Accuracy of diagnosis in RH 
FCM was concordant with the diagnosis of RH in 97% of 172 samples. In four 
aspirates with final diagnosis of RH both FCM and IC suggested a possibility of 
lymphoma. In the first case FCM showed a K/L ratio of 10.6 and cytology 
showed a mixed-cell population of small lymphocytes and relatively large blast-
like cells. Clonality analysis by IC was not representative due to background 
staining. In the second case a subpopulation of monoclonal lambda CD10+ B 
cells with high Bcl-2 expression was found. Therefore, a possible partial 
engagement of FL was reported by FCM. In these two patients a subsequent 
lymph node biopsy could not confirm a diagnosis of lymphoma and Ig heavy-
chain rearrangement analysis showed a polyclonal pattern. In another patient 
FCM revealed a subpopulation of B cells expressing dim kappa, dim CD5 and 
high levels of Bcl-2, indicating thus suspicious lymphoma. The IC findings 
were discordant to FCM by showing dominant lambda-positive B-cells (K/L 
0.6). Lymph node excision biopsy was not performed in the latter two patients, 
but FISH analysis showed normal chromosomes 11, 14 and 18. Importantly, 
none of these patients developed lymphoma during two-year clinical follow-up. 
In the fifth discrepant sample FCM showed dim kappa positivity in the CD19+ 
B-cell population, but FNA cytology and IC were concordant with infectious 
mononucleosis, which was later confirmed by laboratory tests. 
 
 
 1.3. Diagnostic parameters obtained from FCM panel 
1.3.1. B-cell and T-cell counts 
Frequencies of B cells, T cells and CD4/CD8 ratio determined by FCM in 
different NHL categories are given in Table 9.  
 
The B-cell count was significantly higher in LG-NHL as compared to RH: 
 P  0.001 for FL, CLL, IC/LPL, MALT/NMZL 









%CD19+ %CD7+ CD4/CD8 
FL 64.8 ± 18.2 (80) 26.1 ± 14.9 (80) 3.9 ± 2.7 (80) 
CLL 79.5 ± 13.3 (58) 16.6 ± 12.5 (58) 3.6 ± 2.1 (58) 
IC/LPL 79.1 ± 13.6 (10) 17.8 ± 11.5 (10) 3.7 ± 2.4 (10) 
MALT/NMZL 69.7 ± 19.8 (23) 19.6 ± 15.1 (23) 3.6 ± 2.2 (23) 
MCL 82.2 ± 20.5 (11) 12.9 ± 15.0 (11) 1.8 ± 1.6 (11) 
HG-NHL 50.4 ± 25.3 (35) 25.7 ± 19.5 (35) 2.0 ± 2.1 (35) 
T-NHL 27.6 ± 21.7 (17) 61.6 ± 22.3 (17) 7.8 ± 7.2 (15) 
RH 045.6 ± 17.6 (172) 044.9 ± 17.1 (172) 04.5 ± 2.9 (172) 
Values are mean ± standard deviation (number of cases).  
Abbreviations: CLL, chronic lymphocytic leukemia, FL, follicular lymphoma; HG-NHL, high-
grade B-cell non-Hodgkin’s lymphoma; IC/LPL, immunocytoma/lymphoplasmocytic lymphoma; 
MALT/NMZL, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue 
type/nodal marginal zone lymphoma; MCL, mantle cell lymphoma; RH, reactive hyperplasia; T-
NHL, T-cell non-Hodgkin’s lymphoma. 
 
 
No difference in B-cell counts was found between RH and HG-NHL (P = 
0.998). T-cell counts showed a significant difference between RH and all B-cell 
NHL categories (P  0.001). Among B-cell lymphomas B-cell count was lowest 
in HG-NHL, with a significant difference between HG-NHL and categories of 
LG-NHL except for FL (P = 0.085): 
 P  0.001 for CLL, P = 0.001 for IC/LPL 
 P = 0.041 for MALT/NMZL 
 P = 0.007 for MCL. 
 
We also found a significant difference in B-cell count and T-cell count between 
CLL and FL (P  0.001 for both cell subsets). Results of statistical analysis 




1.3.2 K/L ratio 
K/L was assessed within a gated CD19+ B-cell population. On average, K/L in 
RH was 1.7 (median 1.6, range 0.4–4.7). Of 222 B-cell NHL samples 128 
(58%) expressed monoclonal kappa and 77 (35%) monoclonal lambda. We did 
not find sIg expression in eight cases (3%) (four HG-NHL, three FL and one 
CLL). Two of these cases were also negative for both light chains by IC. IC 
showed cytoplasmic kappa expression in one sample and cytoplasmic lambda in 






In nine (4%) lymphoma samples (one of anaplastic B-cell lymphoma, two of 
TCRBCL, five of DLBCL and one MALT/NMZL) FCM showed polyclonal B-
cells. Two of these samples were monoclonal for kappa and one for lambda by 
IC. In five samples clonality could not be demonstrated by IC due to 
background staining. K/L staining by IC was not performed in one case of 
recurrent MALT/NMZL because of characteristic cytologic findings. 
 
 
1.3.3. CD4/CD8 ratio 
The CD4/CD8 ratio was highest in RH (4.5 ± 2.9) and lowest in MCL (1.8 ± 
1.6, P = 0.002 between RH and MCL) and HG-NHL (2.0 ± 2.1, P < 0.001 
between RH and HG-NHL), Table 9. Among different lymphoma categories, 
CD4/CD8 ratio was significantly lower in MCL and HG-NHL than in FL  
(P = 0.013 and P = 0.001, respectively) and lower in HG-NHL than in CLL  
(P= 0.008). When only histopathologically confirmed cases were included in 
statistical analysis, the results remained the same. 
 
 
1.3.4. Bcl-2 expression 
Expression of Bcl-2 was examined in 72 cases of FL, 52 cases of CLL, eight 
cases of IC/LPL, 18 cases of MALT/NMZL, 10 cases of MCL, 29 cases of HG-
NHL, and 137 cases of RH (Figure 7).  
 
 
Figure 7. MFI of Bcl-2 fluorescein isothiocyanae (FITC) monoclonal antibody in B 





There was no significant difference between FL and HG-NHL and between RH 
and MALT/NMZL. 
We found similar levels of Bcl-2 expression in T cells in B-cell NHL (MFI 
94.7 ± 44.7) and RH (MFI 94.8 ± 28.3). In contrast, malignant B cells had 
significantly higher mean Bcl-2 MFI values (266.3 ± 207.6) than did reactive 
CD10- B cells (105.3 ± 31.6). Furthermore, normal germinal center CD10+ B-
cells in RH expressed considerably lower levels of Bcl-2 (MFI 54.4 ± 30.9) than 
did T cells and CD10- B cells. The mean MFI value for Bcl-2 in malignant B 
cells was highest in FL (347.0 ± 248.6), Figure 7. 
Statistical analysis of Bcl-2 expression showed that B cells in RH samples 
expressed significantly lower levels of Bcl-2 than did B cells in lymphomas 
(Figure 7). 
In HG-NHL we noted a heterogeneous Bcl-2 expression. Ten of 29 HG-
NHL samples were considered “low” in Bcl-2 because the level of Bcl-2 
expression was lower than or equal to that of reactive T cells. In nine samples of 
CD10+ HG-NHL very high levels of Bcl-2 were found (MFI 440.6 ± 268.1). 
We also analyzed corrected MFI values for Bcl-2 defined as the ratio of Bcl-
2 MFI in malignant B cells to that in T cells from the same sample. Analysis 
confirmed the results obtained with MFI alone. The highest corrected MFI value 
for Bcl-2 was found in 
 FL (3.69 ± 2.62) and the lowest value was found in RH (1.14 ± 0.27). 
 
We found no substantial overlap between Bcl-2 MFI in B cells of RH and B-
cell NHL. Only in nine cases results obtained in reactive B cells exceeded the 
first quartile of corrected MFI value for Bcl-2 of malignant B-cells. The first, 
second, and third quartile values of corrected Bcl-2 MFI in B cells were 
 0.97; 1.10 and1.27 in RH and  
 1.55; 2.34 and 3.40 in B-cell NHL. 
 
Statistical analysis of Bcl-2 expression in histopathologically confirmed cases 
of B-cell NHL and RH showed similar results. 
The addition of a moAb combination that included Bcl-2 was especially 
helpful in lymphoma samples with presence of rests of normal germinal centers. 
In these samples the results of K/L determination could be misleading, but a 
population of cells with high Bcl-2/CD10 expression could allow the correct 
diagnosis. Further, in other cases determination of K/L could be difficult due to 
weak or negative expression of sIg. We found 49 such cases (30 of FL, 10 of 
HG-NHL, five of MALT/NMZL, three of CLL and one of MCL). Of those, 
Bcl-2 expression was analyzed in 39 cases. In 35 of these, high expression of 
Bcl-2 supported a lymphoma diagnosis. In addition, Bcl-2 analysis helped to 
establish a diagnosis in one case of CLL, one of HG-NHL, and three of sIg-
negative FL. 
Of particular interest was one case of primary DLBCL in which K/L staining 




sIg negative). These large cells demonstrated a CD10+/CD19+ immunopheno-
type with very high levels of Bcl-2. By IC the malignant large cells expressed 
cytoplasmic lambda and had a proliferation rate of 50%. 
 
 
2. Prognostic relevance of MRD detected by FCM  
in young adult AML (Paper II) 
2.1. Frequency of aberrant phenotype in AML 
AML blasts from 93.5% of all patients (58/62) and 94% of those in patients in 
morphological CR (50/53) expressed LAIP at diagnosis. Aberrant phenotypes 
were divided into four groups (San Miguel et al., 1999; Terstappen et al., 1992): 
 Cross-lineage infidelity (n=32) 
 Asynchronous antigen expression (n=48) 
 Antigen over-expression (n=9) 
 Lack of antigen expression (n=5). 
 
Blasts from 28 of 50 patients (56%) expressed highly aberrant phenotypes 
(mainly cross-lineage infidelity) and blasts from 22 patients (44%) had aberrant 
phenotypes, based mostly on maturation asynchrony (Table 10). At diagnosis 
13, 20, seven and five patients expressed one, two, three and four LAIP, 
respectively. 
 
Table 10. Aberrant phenotypes applied in MRD studies 
Aberrant phenotype No (%) 





Antigen over-expression 9 (10) 
CD34++ 9 
Antigen under-expression 5 (5) 
CD33- 5 







(CD34+,CD117+)/CD14+ or CD65+/My+ 5 
Total 94 aberrant phenotypes were detected in 45 patients.  




2.2. Prediction of survival by MRD 
MRD was analyzed at the first time-point in 43 patients in morphological 
remission and at the second time-point in 31 patients. MRD was evaluated at 
both time-points in 30 patients. MRD was detectable in 32 (74%) patients at the 
first time-point and in 17 (55%) at the second time-point. The mean MRD 
levels were 0.23% (median 0.13%, range 0.01–2.48%) after the induction and 
0.23% (median 0.06%; range 0.04–2.0%) after the end of chemotherapy or 
before transplantation. By Cox analysis, detectable MRD after the induction did 
not predict either RFS or OS, but there was a trend for longer RFS in patients 
with no detectable MRD at the second time-point (P = 0.061). 
Prolonged RFS and OS was found in patients subjected to SCT as compared 
to the remainder (median RFS 53.5 m vs 8 m, P < 0.001 and median OS 54,5 m 
vs 14,3 m P = 0.001, respectively). However, by log-rank test MRD1 and 
MRD2 positive young adult AML patients had significantly shorter five-year 
RFS than patients with no detectable MRD {51% versus 90% for time-point (1) 
(P = 0.044) and 42% versus 85% for time-point (2) (P = 0.039), respectively}. 
OS was not significantly different between MRD1 and/or MRD2 positive and 
negative patients. The percentage of blasts in BM at diagnosis, absolute WBC 
count, Hb levels, platelet count, number of cycles to achieve mCR, and 
cytogenetic risk group were not significant predictors of RFS and OS.  
 
 
2.3. Prognostic significance of SCT in relation to MRD status 
2.3.1. Allo-SCT in relation to MRD 
Since SCT was the only significant prognostic factor in the studied group of 
AML patients we decided to investigate how this therapy influenced survival of 
MRD positive and MRD negative patients. For this analysis, the patients were 
divided into 4 categories: 
 no detectable MRD and allo-SCT; 
 detectable MRD and allo-SCT;  
 no detectable MRD and no allo-SCT; 
 detectable MRD and no allo-SCT.  
 
These groups had significantly different RFS based on both MRD1 and MRD2 
(Figure 8 i and ii) and showed a trend for difference in OS (P = 0.069) based on 
MRD2. MRD1 and/or MRD2 positive patients, who did not undergo allo-SCT, 
had the worst outcome (five-year RFS 24% and 20%, respectively; and OS 34% 
and 35%). MRD positive patients that were subjected to allo-SCT had similar 
cumulative RFS (Figure 8 i and ii) when compared to patients who were MRD1 
and/or MRD2 negative. Similar OS was also observed in both these groups 






2.3.2. Auto-SCT in relation to MRD 
During 1994–1997 eligible AML patients were included in an extended British-
Italian-Swedish phase II trial of auto-SCT as consolidation treatment in first 
mCR. The treatment results have been promising. Since auto-SCT improved 
RFS and OS, we analyzed the potential impact of auto-SCT on RFS and OS in 
the MRD positive young adult AML patients in more detail. Indeed, MRD1 
and/or MRD2 positive patients subjected to auto-SCT had significantly better 
RFS (Figure 8 iii and iv) than mCR patients who received only conventional 
post-induction chemotherapy. However, the comparison of RFS (Figure 8 iii 
and iv) showed that MRD positive patients, who underwent allo-SCT had a 
significantly better prognosis as compared to patients who received auto-SCT or 
conventional chemotherapy. The five-year OS was also significantly better in 
allo-SCT patient group than in auto-SCT or conventional chemotherapy patient 
groups {67%, 46 % and 31% for the first time-point (P = 0.021) and 75%, 53% 
and 25% for time-point two (P = 0.046), respectively}. 
 Figure 8. Relapse-free survival (RFS) of younger adult AML patients divided 





MRD status was studied after induction treatment (i and iii) and at the end of 
post-remission chemotherapy or before stem cell transplantation (ii and iv).  
i and ii: AML patients 19–60 years old were divided in four groups: no 
detectable MRD (MRD-) and allo-SCT ( ); detectable MRD (MRD+) and allo-
SCT ( ); MRD- and no allo-SCT ( ); and MRD+ and no allo-SCT ( ). MRD+ 
patients who received allo-SCT had similar RFS to MRD- patients who did not 
receive allo-SCT. 
iii and iv: Only MRD+ patients were considered. The MRD+/no allo-SCT 
patient group was divided into two subgroups: auto-SCT ( ) and only 
conventional chemotherapy ( ). MRD+ patients subjected to allo-SCT ( ) had 
significantly longer RFS after the induction treatment (iii) or before stem cell 
transplantation (iv) than patients who received auto-SCT ( ) or only 
conventional chemotherapy ( ). 
 
 
3. DC levels in BM evaluated by FCM  
in childhood ALL (Paper III) 
3.1. DC levels in children with ALL at diagnosis 
DC levels in BM at diagnosis were evaluated in seven children with preT-ALL 
and 62 with preB-ALL (Table 11). We found a profound deficiency of both DC 
subset levels in most patients. Only two patients (one preB-ALL (SI), one preT-
ALL) had DC subset levels within the reference range. In the preB-ALL HR 
patients, we found a complete absence of both DC subsets. In the SR preB-ALL 
(II) group only one of 28 patients (4%) had very low levels of DCs (both pDC 
and mDC 0.01%). In the SR preB-ALL (SI) group, low levels of pDCs (mean 
0.10%) were found in 30% and mDCs (mean 0.06%) in 22% of patients. 
Therefore, the levels of pDC and mDC in preB-ALL (SI) group were 
significantly higher than in B-ALL HR group (P < 0.001 for pDC and P = 0.012 
for mDC). The levels of pDC were also significantly higher in the SR preB-
ALL (SI) than in the SR preB-ALL (II) group (P = 0.007) and the levels of 
mDC showed the trend (P = 0.053) for higher numbers in the SR preB-ALL (SI) 
group. 
In the preT-ALL group, three patients (43%) had detectable pDCs (mean 
0.11%) and two of patients (29%) had mDCs (0.04%; 0.28%). The levels of 
pDCs and mDCs were significantly higher in preT-ALL patients as compared to 














































































































































































































































































































































































































































































































































































3.2. Correlation of DC subset levels  
with other haematological values at diagnosis 
The median neutrophil counts at diagnosis were 10.9 x 109/L (range 0.6 –16.4 × 
109/L) for preT-ALL and 0.45 × 109/L, (range 0.0–5.2 × 109/L) for preB-ALL 
patients. We found a positive correlation between blood neutrophil counts and 
levels of both DC subsets in BM (P = 0.005; r = 0.331 and P < 0.001; r = 0.441 
for pDC and mDC levels, respectively). pDC levels, but not mDC levels, also 
correlated with platelet counts (P = 0.010). There was no correlation between 
DC levels and Hb values. 
 
 
3.3. Regeneration of DCs during treatment 
The DC levels in the BM increased in parallel with the total BM cellularity, 
which was on average 10% at day 15 (week 2), 30% at day 29 (week 4), 50–
70% at day 50 (week 7) and 70–90% onwards. There was no significant 
correlation between pDC and mDC levels in the BM with peripheral WBC 
count. Detailed data on pDC regeneration is presented in Table 12 and Figure 9 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Median levels of plasmocytoid DCs (pDC) (a,b) and myeloid DCs (mDC) (c,d) 
in bone marrow at indicated time-points during treatment according to NOPHO 
ALL-2000 protocol (see Figure 3) are given. The median hospital control values 
are indicated at each plot (         ) with 95% confidence intervals (dotted lines). 
Data for high-risk (HR) and standard-risk (SR) patients are shown as separate 
curves. Error bars represent 95% confidence interval. In HR group 18, 13, 15, 
18, 18, nine and eight patients were analyzed at diagnosis, week 2, 4, 7, 15, 28, 
and 104, respectively. In SR group 51, 47, 52, 53, 45, 13 and 12 patients were 
analyzed at diagnosis, week 2, 4, 7, 15, 30 and 130, respectively. End of 
treatment was at 104 weeks in the HR group and 130 weeks in the SR group. 
 
 
3.3.1. Regeneration of pDC subset 
At day 15 (week 2), all HR patients had already detectable pDCs in BM 
samples and no increase of pDC levels between days 15 (week 2) and day 29 
(week 4) was found. At day 15 (week 2), pDC were detected in 67% and 58% 
of patients from preB-ALL (SI) and (II) groups, respectively, and at day 29 
(week 4), in 96% and 89% of patients from preB-ALL (SI) and (II) groups, 
respectively. The levels of pDC increased significantly between days 15 (week 
2) and 29 (week 4) in both SI and II groups (P < 0.001). However, at day 29 
(week 4) the levels of pDC in both SR and HR groups remained significantly 
lower than reference levels (P < 0.001, respectively).  
At day 50 (week 7) pDCs were detected in all analyzed BM samples and the 
levels reached the HC group levels in both SR and HR patients (Figure 9). The 
peak of pDC regeneration was found at day 106 (week 15) in HR patients and at 
the beginning of Maintenance-I (week 30) in the SR group (Table 12; Figure 9). 
These two time-points were comparable, since in both groups BM was sampled 
two weeks after the administration of chemotherapy. At these time-points, the 
levels of pDCs in patients were significantly higher than those of HC group (P = 
0.008 and P = 0.032 for HR and SR patients, respectively). After the peak in the 
pDC regeneration, we observed a decrease to levels within reference range 
(Table 12; Figure 9). pDC levels remained stable at the end of treatment and at 
six months after the end of chemotherapy. 
 
 
3.3.2. Regeneration of mDC subset 
The mDC regeneration followed similar pattern to the pDC regeneration in both 
HR and SR patients (Table 12; Figure 9). At day 15 (week 2), mDCs were 
detected in BM samples from 71% of preB-ALL (SI) patients, 58% of preB-
ALL (II) patients and in all HR patients. At day 29 (week 4), mDCs were 
detected in 96% of preB-ALL (SI) patients and 89% of preB-ALL (II) patients. 
However, the mDC levels both in SR and HR groups remained below the HC 


































































































Illustration of DC subset analysis in a BM sample from a representative SR 
group patient treated according to NOPHO ALL-2000 intermediate intensity 
treatment protocol (see Figure 3) is presented in Figure 10.  
DC levels were evaluated from single four-color Lineage (Lin) cocktail 
(CD3, CD14, CD16, CD19, CD20 and CD56)/CD123/HLA-DR/CD11c flow 
cytometry panel (Figure 6) Upper row shows the level of CD123+/Lin- 
plasmacytoid DCs (pDCs) at indicated time points (red dots). The middle row 
shows the level of CD11c+/Lin- myeloid DCs (mDCs) at indicated time points 
(green dots). DC subsets were quantified as percentage of total BM events (red 
color indicates the level of pDCs and green color the level of mDCs). The lower 
row illustrates that pDCs and mDCs express high levels of HLA-DR, mDCs 
show higher HLA-DR expression than pDC subset. Analysis was performed by 
Paint-A-Gate software (BD). 
 
The mDC levels reached the reference range at day 50 (week 7) in all groups of 
patients (Figure 9). The peak of mDC regeneration was detected in HR patients 
at day 106 (week 15) and in SR patients at the beginning of Maintenance-I 
(week 30). At these time-points, the levels of mDC were significantly higher 
than the control levels (P = 0.024 for HR group and P = 0.041 for SR group). At 
the end of treatment the mDC levels in HR patients did not differ from the HC 
levels. However, in SR group, mDC levels decreased further becoming 
significantly lower than reference values (P = 0.032) and remained lower in the 
follow-up samples taken six months after the end of chemotherapy (P = 0.028). 
 
 
3.4. DC levels in relation to MRD 
We were also interested if the levels of DC subsets were related to the presence 
of MRD in BM samples of patients under treatment. For that analysis we 
divided patients in the MRD-positive and MRD-negative categories and 
compared the DC levels in BM samples obtained at day 15 (week 2), 29 (week 
4) and 50 (week 7) from these two groups. No significant differences were 
found in BM DC levels between MRD-positive and MRD-negative patients at 
day 15 and 29. At day 50, MRD-positive patients (N=13) had significantly 
higher pDC levels in BM than MRD-negative group (N=55) (median 0.36%, 






Figure 11. Dendritic cell (DC) subset levels in relation to minimal residual disease 
(MRD) levels at the end of Induction treatment according to NOPHO 2000 protocol. 
 
Patients who were MRD positive at the end of Induction treatment (day 
50/week 7) had significantly higher pDC levels than patients who were MRD 
negative at this time-point. The levels of myeloid DC did not differ between 
MRD positive and negative patients groups. DC subsets were quantified as 




3.5. DC levels in refractory/very slow responding ALL patients 
Three of studied patients were still not in mCR at day 50 (week 7). In one preT-
ALL patient with refractory disease we could detect DC subsets at the very low 
levels (<0.1%). Another slow-responding preT-ALL patient, who reached 
morphological CR at day 58, had normal DC subset levels in BM at day 75, 
when the MRD level in BM was 0.8%. When this patient subsequently relapsed, 
both DC subsets were detectable (pDC 0.1% and mDC 0.03%), but disappeared 
from BM when the disease progressed to refractory stage, Figure 12. The third 
patient with HR preB-ALL had a very slow response to treatment achieving 
mCR at day 64 with BM MRD level 1.1%. At this time-point, both DC subsets 






Figure 12. Dendritic cell levels in relation to levels of leukemic cells in a patient with 
precursor T-cell acute lymphoblastic leukemia (preT-ALL) resistant to treatment. 
 
preT-ALL cell levels were measured as percentages of cells positive for TdT 
FITC/CD7 PE/cytoplasmicCD3 PerCP /CD34 APC. Levels of pDC and mDC 







Immunophenotyping with multiparameter FCM is a rapid and sensitive method 
to detect small cell populations in a variety of cellular background. FCM is 
especially useful to detect lymphoid abnormal cell populations, but FCM is 
increasingly used in detecting small populations of abnormal blasts in acute 
leukemias and detecting different cell populations in the immune system. The 
thesis includes three studies where FCM was used a principal method in 
detecting cell populations of interest. The first study was focused for accuracy 
of lymphoma diagnosis in FNA material. The second study was aimed to 
investigate the power of FCM to detect MRD in young adult AML patients and 
especially to evaluate the prognostic significance of MRD in relation to 
transplantation. The third study investigated DCs, the central cells in immune 
system which orchestrate the whole immune response in childhood ALL. 
 
 
1. The usefulness of FCM in lymphoma  
diagnosis in FNA 
The WHO classification of haematopoietic and lymphoid tumors classifies 
lymphoid malignancies into distinct biologic entities based on morphology, 
immunophenotype, genetics and clinical features (Jaffe, 2001). The relative 
importance of each of these methods varies among different lymphomas, but 
generally biopsy for histologic examination and demonstration of clonality is 
required. The diagnosis of NHL on cytologic material only has been controver-
sial (Hanson, 1994). However, when FNA is combined with immuno-
phenotyping by IC, the accuracy of NHL detection exceeds 90%. However, 
immunophenotyping can also be accomplished with FCM. Both techniques 
have advantages and limitations. The main advantage of IC over FCM is the 
requirement of a small number of malignant lymphoma cells and the preserva-
tion of cellular morphology. Intensity of staining, staining pattern and 
background can be assessed easily. Moreover, fragile neoplastic cells which 
could be destroyed during FCM preparation and analysis could be successfully 
assessed in cytospins. The disadvantage of IC is that the technique is time-
consuming, routinely only one antigen can be assessed per cell and scoring is 
semi-quantitative. FCM is a rapid and sensitive method, which allows to assess 
several antigens on one cell simultaneously. Current techniques allow detection 
of intracytoplasmic antigens, closing thus the gap between FCM and IC. 
Furthermore, FCM provides quantitative results and can detect small abnormal 
cell populations in reactive background. These FCM features significantly 
improve the diagnostic sensitivity and therefore are particularly useful in 
lymphoma diagnostics. However, the main disadvantage of FCM is 




In our study we demonstrated that a simple four tube four-color FCM panel 
allows quick and precise classification of NHL and detection of RH in FNA 
material. The inclusion of Bcl-2 into FCM was useful because malignant B cells 
in most samples expressed a higher levels of Bcl-2 than did normal B cells and 
T cells. In our study FCM and IC were equally effective in distinguishing NHL 
from RH and also in the diagnosis of primary and recurrent lymphomas. 
We found in literature search two studies that directly compared FCM with 
IC on FNA aspirates in large series of cases (Robins et al., 1994; Simsir et al., 
1999). These studies demonstrated that FCM and IC can be used inter-
changeably and the overall concordance of the FCM and IC results was similar 
to that in our study. FCM has been used an aid to FNA diagnostics in several 
other studies, showing the rate of accuracy more than 90% (Dunphy and Ramos, 
1997; Meda et al., 2000; Nicol et al., 2000; Dong et al., 2001). 
In our study FCM panel suggested lymphoma in five samples finally 
diagnosed as RH. In four of these samples also IC suggested lymphoma. 
However, similar cases have been reported in literature. Our results are in 
agreement with the study of Meda et al (Meda et al., 2000) who reported four 
cases of RH that were suggestive of lymphoma in FNA. Another study by Levy 
et al (Levy et al., 1983) described 12 patients with RH, in whom sIg studies 
showed monoclonal Ig staining pattern. 
FCM was especially useful in detecting low-grade B-cell lymphomas, 95% 
of cases were diagnosed and classified accurately. The only problematic 
category was CD10- FL. Interfollicular lymphoma cells may lack CD10 (Dogan 
et al., 1998) and in these cases FCM is not able to diagnose lymphoma subtype 
correctly. 
The diagnostic accuracy in the detection of HG-NHL was much lower than 
that of LG-NHL. However, our results are similar to the study of Verstovsek et 
al (Verstovsek et al., 2002) who reported 27% false negative FCM results in 
HG-NHL. Preparation of FCM may lead to preferential loss of large cells due to 
increased death. We noted that in HG-NHL, acquired cell counts were 
approximately 1000 events lower than average: 7831 vs 8874, respectively. In 
addition, B-cell counts were lowest in HG-NHL. 
Diagnosis of T-cell NHL by FCM is complicated because there is no 
sensitive marker for clonality. We could detect a pathologic immunophenotype 
in T-NHL in 53% of cases. This result is similar to report by Meda et al (Meda 
et al., 2000), but the frequency of a pathologic phenotype was somewhat lower 
than obtained by Yao et al (Yao et al., 2001) who found aberrant expression of 
T-cell markers in 67% (14 of 21) of peripheral T-NHL samples. 
We also studied the usefulness of FCM analysis of Bcl-2 expression in 
differential diagnosis of malignant lymphoma. This has been previously investi-
gated in only two studies of lymph node biopsies (Cornfield et al., 2000; Cook 
et al., 2003). Cornfield et al reported that simple dual staining with monoclonal 
antibodies to Bcl-2 and CD20 is useful in differentiating neoplastic from benign 





a three-color FCM panel using antibodies against CD10, CD20 and Bcl-2. Our 
four-color FCM panel had an advantage allowing simultaneous evaluation of 
Bcl-2 expression in B and T cells and, if present, in CD10+ B cells. Using this 
approach non-malignant T cells present in the sample served as internal control 
for the comparison of levels of Bcl-2 expression. Similarly to previous reports 
we found that the presence of CD10+ B cells with high Bcl-2 expression was 
highly predictive for FL (Cornfield et al., 2000; Cook et al., 2003). In contrast, 
CD10+ B cells in RH expressed much lower levels of Bcl-2 than did T cells and 
CD10- B cells. We also noted high Bcl-2 expression in most cases of LG-NHL, 
which was not investigated in detail previously (Cook et al., 2003). Cornfield et 
al (Cornfield et al., 2000) surprisingly found that T cells express higher levels of 
Bcl-2 in FL than in RH. In contrast, we found Bcl-2 expression in T cells very 
similar between RH and B-cell NHL. Analysis of Bcl-2 expression was most 
useful in FL cases with partial lymph node involvement with nests of reactive 
germinal centers that made evaluation of light-chain restriction difficult. In HG-
NHL Bcl-2 expression was less informative because malignant B cells may 
downregulate Bcl-2 (Lai et al., 1998). Our results are similar with the report of 
Menendez et al (Menendez et al., 2004) who also found that malignant B cells 
in BM and peripheral blood samples from patients with mature B-cell 
neoplasms, except BL, express consistently higher levels of Bcl-2 than their 
normal counterparts. 
The major weakness of the study is that histopathologic confirmation was 
available in only 124 of 424 (29%) of cases. Biopsy was mainly performed in 
diagnostically difficult cases or when histopathology was needed for making 
treatment decisions. However, cytologic diagnosis was concordant with 
histopathology in all lymphoma cases. Unfortunately, biopsy is not always 
readily available, for example when enlarged lymph nodes are present only in 
abdomen or thorax. If in such cases patients are too fragile for operation, FNA 
remains an important option for lymphoma diagnosis. In addition FNA could be 
helpful selecting the most representative malignant lymph node for biopsy if 
multiple sites are involved from suspect lymphoma.  
Based on the study results, we recommend first to perform a stain of an FNA 
smear. If small to medium-size lymphatic cells predominate, indicating low-
grade lymphoma, FCM should be the method of choice for immuno-
phenotyping. However, when large cell predominate, IC should be preferable 
due to a high false-negative rate of FCM. It has to be noted that Hodgkin’s 
lymphoma and some NHLs like TCRBCL and anaplastic large cell lymphoma 
cannot be reliably detected by FCM. For the best diagnostic accuracy a strong 






2. The usefulness of FCM in detecting MRD  
in young adult AML 
Studies of childhood and adult AML have shown that the levels of MRD 
detected either early after induction or later after consolidation are powerful 
prognostic factors. We focused on the prognostic significance of MRD in 
relation to SCT in young adult AML patients 19–60 years old. Allo-SCT was 
performed in 36% (16/45) of patients and 33% (15/45) underwent auto-SCT. 
Fourteen patients (31%) were treated with conventional chemotherapy only. In 
our study MRD levels detected either after induction or at the end of post-
remission chemotherapy or before SCT were not predictive for RFS or OS, but 
there was a trend for a longer RFS in patients with no detectable MRD at the 
end of chemotherapy or before SCT. Statistically, SCT was the only significant 
prognostic factor. Patients who underwent SCT had significantly longer OS and 
RFS than had patients who received only chemotherapy. However, patients with 
MRD detected after the induction treatment and/or at the end of chemotherapy 
had significantly lower five-year RFS than patients without detectable MRD. 
Patients without detectable MRD had also a slightly but not significantly longer 
OS. 
Since prognosis of AML was predicted only by SCT, we investigated how 
SCT influenced survival of MRD-positive and MRD-negative patients. The 
worst outcome was observed in patients, who were MRD-positive either after 
induction or at the end of treatment and did not undergo SCT. MRD-positive 
patients, who underwent allo-SCT had similar cumulative RFS and OS to 
MRD-negative patients, who did not receive allo-SCT. Finally, MRD-positive 
patients who underwent auto-SCT had worse outcome as compared to MRD-
positive patients who underwent allo-SCT. However, autografted MRD-positive 
patients had significantly longer RFS and OS than patients treated by 
chemotherapy only. Our data indicates that the prognostic significance of MRD 
differs depending on the applied post-remission therapy. Although our study 
included a small number of patients, the results strongly indicate that patients 
who remain MRD-positive after the induction treatment and/or at the end of 
chemotherapy have worse prognosis and benefit from allo-SCT or intensified 
post-remission therapy with auto-SCT. 
We used FCM as a method to detect MRD and therefore several aspects of 
this technique need to be discussed in detail. 
 
 
Applicability and reliability of the FCM method 
In our study we could detect LAIPs in 94% of patients at AML diagnosis. Our 
results are in line with the previous studies by San Miguel et al (San Miguel et 
al., 2001) and Coustan-Smith et al (Coustan-Smith et al., 2003), who reported 
the frequency of LAIPs at diagnosis in 75% and 85% of patients, respectively. 




numerous fluorochromes, demonstrated that at least one LAIP could be detected 
in every studied patient and MRD could be followed by FCM in all AML 
patients. The limitation of this approach was a lower sensitivity due to increased 
use of less aberrant LAIPs that may be present in very low frequencies in 
normal or reactive BM. 
The phenotype changes in AML are the major concern when discussing the 
reliability of FCM detection of MRD, since this phenomenon may lead to false-
negative results. Macedo et al (Macedo et al., 1996) and Baer et al (Baer et al., 
2001) have reported that immunophenotypic shifts occur in 11% of LAIPs. In 
addtion, Voskova et al (Voskova et al., 2004) reported, that in 24% of patients, 
none of the original LAIPs were present in more than 1% of BM cells at relapse. 
Nevertheless, by using several LAIPs, relapse could be detected in virtually all 
patients (Voskova et al., 2004). 
Phenotypic changes occurred frequently also in our study. Major phenotypic 
changes (i.e. loss or gain of an antigen) were found in AML blasts from 9 of 15 
patients (60%), in whom FCM analysis was performed at relapse. The following 
antigens were lost at relapse (each in one case): CD2, CD56 and TdT. At 
relapse AML blasts acquired: HLA-DR in two cases and CD4, CD33, CD34 
and CD38 each in one case. 
In six of the nine patients, the prognostic evaluation of MRD was not 
affected by the loss or gain of individual antigens since other studied LAIPs 
remained aberrant. In the remaining three patients (33%) the change of antigen 
expression occurred in the most aberrant LAIP used for MRD follow-up. 
However, in two of these three patients MRD was still detectable, since a small 
population with the original LAIP persisted during treatment and at relapse. 
Phenotype changes rendered MRD not detectable in only one patient. In this 
patient the CD34+ blast population constituted only 0.2% of total blasts at 
diagnosis. Therefore, a CD34 negative population was selected for MRD 
studies, but the major AML blast population at relapse was CD34 positive. 
Thus, phenotype changes resulted in false-negative MRD measurements in 1 
out of 15 patients (7%) analyzed at relapse. 
We also noted minor changes in antigen expression levels in 33% of relapse 
patients. This indicates a potential interpretation hazard if strictly predefined 
dot-plot gates are used for MRD evaluation. 
A study by Voskova et al (Voskova et al., 2004) showed that LAIP changes 
in AML at relapse may be associated with a biologically different disease, 
especially when there are also changes in cytomorphology and molecular 
genetics. In our study, one phenotype change occurred in a patient with AML-
M0 at diagnosis that at relapse displayed a phenotype consistent with preT-








Sensitivity of the method and clinically relevant MRD levels 
A maximum sensitivity of 10–4–10–5 could be achieved using live-gate 
acquisition approach together with highly aberrant LAIPs (Coustan-Smith et al., 
2003; San Miguel et al., 2001). However, this high level of sensitivity is 
difficult to achieve with less aberrant LAIPs due to very small populations with 
similar phenotypes that could be present in normal regenerating BM. Therefore, 
data from published studies, as well as our study indicate that MRD at cut-off 
level around 0.1% defines the patient group with the highest risk of relapse. 
However, in a study by San Miguel et al (San Miguel et al., 2001) approxi-
mately 30% of patients had MRD level between 0.01–0.1% with a three-year 
cumulative relapse rate of 14%, whereas patients with MRD levels between 
0.1–1% had the relapse rate of 45%. Therefore, MRD levels between 0.01–0.1% 
may also define patients with an increased relapse risk. In our study, relapse 
occurred in four out of six patients who had MRD levels between 0.01–0.09% 




The most relevant time-point for MRD follow-up 
Two studies in adult AML (Feller et al., 2004; San Miguel et al., 2001) and two 
studies in childhood AML (Coustan-Smith et al., 2003; Sievers et al., 2003) 
indicate that early MRD detection i.e. after induction chemotherapy, when the 
first mCR is achieved, is highly significant for prognosis. Two other adult AML 
studies (Kern et al., 2004; Venditti et al., 2000) indicated that the late MRD 
detection, i.e. after post-remission treatment could be more relevant for 
outcome. In our study eight patients had no detectable MRD at both above-
mentioned time-points and none of them relapsed. However, two out of six 
patients who had no detectable MRD at the end of chemotherapy treatment but 
were MRD-positive after induction treatment, suffered relapse. 
 
 
MRD follow-up after the end of treatment 
Only few reports are available on the significance of long-term MRD follow-up 
in AML patients. Results from studies by Feller et al (Feller et al., 2004) and 
Venditti et al (Venditti et al., 2003) indicate that in order to predict relapses 
MRD should be followed at least every three months. 
We followed MRD in 11 patients after the completion of therapy (23 BM 
samples collected at different time-points). Auto-SCT was performed in 10 of 
these patients. MRD was followed at least twice in five patients and once in six 
patients. Of eight patients with no detectable MRD, only two patients relapsed 
within seven months after the last follow-up. In contrast, relapse was detected in 





Finally, two patients, who showed decreasing MRD levels from 0.13% or 
0.07% to MRD-negativity, did not relapse. 
 
 
Relationship of MRD levels with other known prognostic features 
All studies discussed above, have clearly shown that the level of MRD is more 
powerful independent prognostic factor than other known pre-treatment 
prognostic factors such as age, WBC count and cytogenetic risk group. In 
addition, results from a study by San Miguel et al (San Miguel et al., 2001) 
demonstrated that patients with favorable cytogenetics had significantly lower 
MRD levels as compared to patients with intermediate or unfavorable 
karyotypes. Patients who achieved mCR after the first chemotherapy cycle or 
had WBC counts less than 50 x109/l also had significantly lower MRD levels as 
compared to patients who achieved mCR after the second chemotherapy cycle 
or had WBC counts greater than 50 x109/l. Kern et al (Kern et al., 2004) have 
also reported that MRD levels have prognostic impact even within cyto-
genetically defined risk groups. 
In our study we did not find significant correlation between MRD levels and 
age, cytogenetic risk-group and WBC count. However, all analyzed five 
patients with unfavorable cytogenetics had detectable MRD after induction 
treatment and two of them relapsed. Two of these five patients subjected to allo-
SCT and one patient subjected to auto-SCT did not relapse. Two patients had 
favorable cytogenetics and one of them, who remained MRD-positive at the end 
of post-remission chemotherapy, suffered relapse. We performed analysis of the 
significance of MRD in the intermediate cytogenetic risk-group. Patients with 
no detectable MRD after induction had significantly longer cumulative five-
year RFS than patients with detectable MRD (90% versus 49%, P = 0.041). OS 
was also prolonged in patients with no detectable MRD, but this difference did 
not reach to statistical significance. 
Based on the results of the study we recommend FCM based monitoring in 
every AML patient in order to refine and individualize post-remission therapy 
according to treatment response at the submicroscopic level. Since our study 
included a relatively limited number of patients, large prospective studies are 
needed, where MRD is thoroughly followed and used for therapy decisions in 
uniformly treated patient groups. These studies would further improve 
possibilities of treatment stratification in individual AML patient.  
 
 
3. DC levels in BM evaluated by FCM  
in childhood ALL 
DCs originate from CD34+ BM precursor cells and play a pivotal role in the 
development of immune responses and immune tolerance. Very little is known 




investigated DC subset levels in peripheral blood from patients with ALL at 
diagnosis (Maecker et al., 2006; Mami et al., 2004). Both authors reported 
severely reduced levels and impairment function of both mDCs and pDCs in 
patients with B-ALL. However, DC subsets were quantitatively and 
functionally comparable with healthy control group and in patients with preT-
ALL. To our best knowledge, there is no published data on DC subset levels in 
BM obtained at diagnosis of ALL and during ALL treatment. Our study is the 
first to demonstrate a severe deficiency of DCs in BM of childhood ALL at 
diagnosis. Our findings are in concordance with previous studies, which 
demonstrated a severe reduction of DC subsets in blood of ALL patients at 
diagnosis and higher levels in preT-ALL as compared to preB-ALL patients 
(Maecker et al., 2006; Mami et al., 2004). The latter finding can be in part 
explained by correlation of peripheral blood neutrophil counts at diagnosis with 
DC subset levels in BM and higher neutrophil counts in patients with preT-ALL 
as compared to patients with preB-ALL. However, on the contrary to findings 
in peripheral blood (Maecker et al., 2006; Mami et al., 2004), we did not find 
normal levels of pDC and mDC subsets in BM in patients with preT-ALL. This 
discrepancy could be explained by different source of DCs or different antibody 
panels and method of analysis. We performed the DC subsets analysis in whole 
BM and not after Ficoll-densitiy centrifugation. Using four-color analysis we 
evaluated both subsets in the same staining tube. One of the drawbacks of our 
study is that we could not evaluate the absolute numbers of DCs. The cell 
concentration in aspirates could not be assessed since BM samples for flow 
cytometry analysis were diluted in heparinized saline to prevent clotting. BM 
cellularity was evaluated only on BM biopsy sections. 
In preB-ALL patients DC levels were related to the extent of the disease. 
Patients in the SR group had significantly more pDCs and mDCs in BM than 
patients in higher risk groups. These differences may be related to more 
pronounced BM suppression in higher risk groups, especially in patients with 
HR preB-ALL. The relationship between DC levels and BM suppression is also 
supported by the finding that DC levels correlated with platelet and neutrophil 
counts at diagnosis.  
The levels of both DC subsets in BM reached to reference values at the end 
of Induction treatment block (day 50/week 7). Up to day 50 (week 7), treatment 
of patients in both SR and HR groups was essentially identical. The 
regeneration peak of the relative levels of both pDC and mDC subsets occurred 
at the beginning of Consolidation-1 (day 106/week 15) in HR patients and at the 
beginning of Maintenance-1 in SR preB-ALL (II) patient group (week 30). At 
this time points, the relative levels of both pDC and mDC subsets were signi-
ficantly higher than control values. These two time-points were comparable, 
since in both patient groups BM were sampled two weeks after the end of 
previous chemotherapy cycles, which were essentially identical. 
At the end of therapy, the level of pDC subset in BM was comparable to 




was significantly reduced in SR group but not in HR group of patients. Notably, 
the SR group was under treatment 6 months longer than HR group. Therefore, 
the prolonged treatment may have more severe effect on mDC subset by 
comparison to pDC subset. Another explanation is that the suppression of DCs 
could also be related to low WBC counts during Maintenance therapy when 
WBC count is targeted to 1.5–3.5 x109/L. However, at the end of therapy DC 
subsets levels did not correlate with neutrophil and platelet counts. This may 
indicate that at the end of treatment decreased DC levels are not caused only by 
BM suppression. Importantly, mDC subset levels remained significantly lower 
than control values at six months after the end of treatment protocol when BM 
biopsies usually showed normal cellularity. 
DCs provide essential link between innate and adaptive immunity. Immature 
DCs are present in peripheral tissues where they are posed to capture antigens 
and after antigen capture, antigen-loaded tissular dendritic cells migrate through 
afferent lymphatics into draining lymph nodes where they present processed 
antigens to T-cells. It has been demonstrated that the mDC is the predominant 
subtype in the peripheral tissues such as human deciduas (Gardner and Moffett, 
2003), in human lung (Masten et al., 2006; Demedts et al., 2007) and in human 
renal tissue under normal and pathological conditions (Woltman et al., 2007). 
Furthermore, mDC subtype predominates also in human peripheral blood 
(Vakkila et al., 2004; Maraskovsky et al., 2000). However, in primary and 
secondary lymphoid tissues like in human thymus (Bendriss-Vermare et al., 
2001), human tonsils (Summers et al., 2001) and in human BM (Szabolcs et al., 
2003) pDC subtype predomiantes. Further, pDCs have been shown to be the 
major DC subset innately producing cytokines in human lymph nodes (Cox et 
al., 2005). Finally, both mDC and pDC orchestrate the migration of immune 
effectors like T and B cells, launching and shaping adaptive immune response. 
In accordance with above-mentioned published data, we found that pDC is the 
predominant subtype in BM. This finding was true both for non-leukemic (HC 
group) patients and for BM from ALL patients in CR. 
It has be noted, that in addition to pDC and mDC, the third subtype of DC is 
characterized in humans. These cells are lineage marker negative, express high 
levels of HL-DR and co-express CD16 and low levels of CD14. Almeida et al 
have found that the overall frequency of those cells in normal adult peripheral 
blood is 0.72% ± 0.35% of all nucleated cells, which is higher than remaining 
lin-/CD16-/HLA-DR+ DCs (Almeida et al., 2001). The frequency of these 
CD16+ DCs in BM was 0.19% ± 0.15% which was lower than in PB (Almeida 
et al., 2001). The role of these DCs in immune response is not fully established, 
but Kanaya et al have shown that these DCs exhibit weak immunostimulatory 
activity and may play a role in the induction of chronic inflammation (Kanaya 
et al., 2004). In our study we could not evaluate this DC subset since our 
lineage marker combination included CD16. The level of CD16+/HLA-
DR+/CD14-/low DCs at ALL diagnosis and during treatment has to be 




The defects in mDC maturation in cancer patients attract great attention 
(Gabrilovich, 2004). It has been found that patients with breast and head and 
neck cancer had significantly reduced mDC, but not pDC levels (Hoffmann et 
al., 2002; Della Bella et al., 2003). Furthermore, this reduced mDC levels were 
restored after cancer removal (Hoffmann et al., 2002; Della Bella et al., 2003). 
We also observed no regeneration of DC cells in three patients who did not 
achieve mCR, indicating suppression of DC regeneration by remaining 
leukemia. It has been reported that in cancer patients DCs exhibit several 
functional abnormalities, such as decreased expression of co-stimulatory 
molecules (Nestle et al., 1997; Troy et al., 1998) insufficient T-cell stimulatory 
capacity and accumulation of immature DCs (Nestle et al., 1997; Gabrilovich, 
1997). The accumulation of immature DCs may be especially important, since 
they induce T-cell tolerance (Chaux et al., 1997; Enk et al., 1997; Bonifaz et al., 
2002). 
The major impact of decreased mDC levels on immune functions is 
emphasized by a concept that mDCs are central cells in T-cell priming that 
transfer signals from the innate immunity to adaptive immune system (Dubsky 
et al., 2005). It is established that children treated for ALL may have profound 
impairment of the immune system (Brodtman et al., 2005; Nilsson et al., 2002; 
Smith et al., 1995). 
It could be clinically relevant to establish if there a relationship between DC 
levels at diagnosis or at early time-point during treatment and clinical outcome. 
We observed that MRD-positive patients had significantly higher pDC levels in 
the BM than the MRD-negative group at the end of Induction treatment. 
Follow-up time is too short to determine the prognostic significance of this 
finding. However, this observation is in agreement with a recent study reporting 
negative prognostic impact of high pDC counts at diagnosis in childhood cancer 
patients (Vakkila et al., 2004). It has been suggested that pDC may induce 
tolerance of the immune system against cancer cells (Wei et al., 2005). Further, 
hepatic lymph nodes of patients with hepatocellular carcinoma have signi-
ficantly reduced numbers of mDCs and elevated levels of pDCs in the T-cell 
areas when compared to lymph nodes from patients with viral hepatitis without 
involvement of cancer (Tang et al., 2006). Additionally, it has been shown that 
pDCs accumulate in the ovarian carcinoma microenvironment where they are 
able to induce suppressive CD8+ regulatory T-cells (Wei et al., 2005). 
We acknowledge that the major drawback of our study is that we did not 
study the function of DCs due to shortage of BM cells. Studies in future should 
aim on investigating DC function ex vivo at different time-points during and 
after ALL therapy. 
Based on the results of the study we propose that reduced levels of DC 
subsets may be one of the important factors in the impairment of the immune 
system in children after treatment for ALL. Future studies should focus on the 
functional status of DC subsets in ALL patients after treatment. The relevance 






Multiparametric FCM is useful to detect the correct NHL subtype and for NHL 
differentiation from reactive hyperplasia. 
 FCM allows precise lymphoma classification from FNA material, a panel of 
four tubes of four-color antibody combinations is reliable of NHL diagnosis 
of 90% of samples. 
 Staining for Bcl-2 is helpful for differentiation between RH and NHL, 
especially in samples with partial lymph node involvement. 
 FCM technique is more efficient in detecting LG-NHL than HG-NHL due to 
the fragility and preferential loss of large lymphoma cells. 
 FCM technique is more reliable in detecting B-NHL than T-NHL due to the 
lack of sensitive marker for clonality. 
 
MRD analysis by flow-cytometry may be used for refining the selection of 
therapeutic strategies and improving clinical outcome in individual patients.  
 MRD assessment by FCM is applicable over 90% of patients with AML and 
is reliable. Due to possibility of phenotype change in AML blasts, for 
efficient MRD monitoring two or more LAIPs should be followed. 
 The prognostic significance of MRD levels in AML patients depends on the 
type of post-remission therapy. 
 Young AML patients who have detectable MRD at the first CR and/or at the 
end of post-remission chemotherapy may benefit from SCT. 
 AML patients in whom MRD is not detectable after induction treatment and 
who remain MRD-negative at the end of post-remission chemotherapy have 
long-term RFS and OS similar to allografted patients. 
 
Children with ALL have a severe deficiency of DCs in BM at diagnosis, which 
is more pronounced in preB-ALL than in preT-ALL. 
 In preB-ALL patients DC levels were related to the extent of the disease: 
children without unfavorable features had significantly more pDCs and 
mDCs than patients with unfavorable prognostic features. 
 DCs subset levels regenerate to reference levels by the end of induction 
treatment according to NOPHO ALL-2000 protocol at day 50/week 7. 
 The regeneration of mDC subset is more severely affected by ALL 
chemotherapy than the pDC subset in SR group, decreasing to significantly 
lower than control levels at the end of chemotherapy and remaining 
significantly reduced at six months after the end of ALL treatment. 
 In patients with treatment-resistant ALL, both pDC and mDC regeneration is 
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SUMMARY IN ESTONIAN 
Läbivoolu tsütomeetria kasutamine pahaloomuliste 
vereloomehaiguste korral 
Läbivoolu tsütomeetria on kaasaegne laseril põhinev meetod rakkude uuri-
miseks, mille abil on võimalik iseloomustada rakkude koostist – rakkude sees 
olevaid valke-, ning markereid, mis asuvad rakkude pinnal. Samuti on võimalik 
määrata rakkude suurust ja granulaarsust. Kuigi läbivoolu tsütomeetriat on 
eelkõige kasutatud immunoloogias lümfotsüütide arvu määramiseks ja nende 
iseloomustamiseks, on tehnoloogia arenedes meetodit hakatud kasutama ka 
pahaloomuliste vereloomehaiguste korral. Hematoloogiliste patsientide luuüdi 
ja lümfisõlmede punktaadid on ideaalsed substraadid, kus saab kasutada uuri-
miseks läbivoolu tsütomeetrilist meetodit. Läbivoolu tsütomeetria võimaldab 
leida suurest rakkude hulgast spetsiifilised rakud, mis eristuvad teatud kindla 
tunnuse järgi, nagu näiteks iseloomulik rakupinna marker. Uuemate mono-
klonaalsete antikehade abil on võimalik uurida täpsemalt erinevaid vereloomest 
pärinevaid rakke ning nende muutusi ravi käigus. Viimastel aastatel kasutatakse 
läbivoolu tsütomeetriat järjest sagedamini vereloomehaiguste diagnoosimisel, 




Uurimistöö peamiseks eesmärgiks oli hinnata läbivoolu tsütomeetria kui 
meetodi rakendatavust pahaloomuliste hematoloogiliste haiguste korral. Täpse-
mateks töö eesmärkideks olid: 
1) hinnata läbivoolu tsütomeetria rakendatavust lümfoomide diagnostikas peen-
nõelbiopsial saadud materjalist.  
2) Hinnata läbivoolu tsütomeetria abil minimaalse residuaalse haiguse olemas-
olu ja selle prognostilist väärtust noortel ägeda müeloidse leukeemiaga 
täiskasvanutel. 
3) Uurida läbivoolu tsütomeetria abil dendriitiliste rakkude arvu ägeda lümfo-
blastse leukeemiaga lastel haiguse diagnoosimise hetkel ja rakkude taastu-
mist keemiaravi ajal.  
 
 
Materjalid ja meetodid 
Uurimisgrupis oli 526 patsienti, 256 meest/poissi ja 270 naist/tüdrukut vanuses 
2 kuud kuni 94 aastat, keda uuriti ja raviti Karolinska Haiglas ja Astrid 
Lindgreni nimelises Lastehaiglas Stockholmis Rootsis ajavahemikul 1994–
2005.  
Lümfoomide diagnostilises uuringus peennõelbiopsial saadud materjalist 




residuaalse haiguse hindamise uuringus oli 45 patsienti ja dendriitiliste rakkude 
arvu määramise uuringus 85 last. 
Lümfoomide diagnostiline uuring tehti 396 patsiendil, kokku 424 peennõel-
biopsiat. Kahekümne kuuel patsiendil teostati biopsia kaks korda ja ühel 
patsiendil kolm korda. Kõikidel nendel juhtudel võeti peennõelbiopsia erine-
vatest kohtadest ja/või erinevatel ajahetkedel. Lümfisõlmi punkteeriti 352 korral 
ja teisi kudesid 72 korral. Peennõelbiopsial saadud rakke ja luuüdi rakke uuriti 
läbivoolu tsütomeetriga. Uurimistöös kasutati FACSCalibur ja FACScan läbi-
voolu tsütomeetreid, mis olid varustatud ‘Lysis II’ või ‘Cell Quest’ programmi-
dega. Rakkude hulga täpsemaks määramiseks kasutati ‘Paint-A-Gate’ arvuti-
programmi. Nii tsütomeetria aparaadid kui andmetöötlusprogrammid olid 
Becton Dickinson korporatsioonilt.  
Minimaalset residuaalset haigust jälgiti kokku 45 patsiendil, kellel keemia-
raviga saavutati täielik morfoloogiline remissioon. Patsientide jälgimise aeg oli 
keskmiselt viis aastat. Minimaalset residuaalset haigust uuriti kahel korral: 
pärast induktsioonravi lõppu ja kas keemiaravi lõppedes või enne autoloogset 
või allogeenset siirdamist. 
Dendriitilisi rakke uuriti 76 ägeda lümfoblastse leukeemiaga lapsel ja ühek-
sal leukeemia kahtlusega lapsel, kelle luuüdi leid osutus normaalseks. Need 
üheksa last moodustasid kontrollgrupi dendriitiliste rakkude arvu hindamisel. 
Ägeda lümfoblastse leukeemiaga lastel uuriti dendriitilisi rakke haiguse diag-
noosimisel, ravi ajal viiel korral, ravi lõppedes ja kuus kuud pärast ravi lõppu. 
Luuüdi dendriitiliste rakkude uurimiseks võeti ajal, mil toimus ka luuüdi 
rutiinne kliiniline uurimine vastavalt raviprotokollile. 
Lümfoomide diagnostiline paneel koosnes neljast neljavärviliset markerite 
kombinatsioonist: (1) lambda/kappa/CD19/CD5, (2) CD23/CD10/CD20/CD19, 
(3) CD4/CD7/CD8/CD3 ja (4) Bcl-2/CD10/CD19/CD3. 
Ägeda müeloidse leukeemia diagnostiline läbivoolu tsütomeetriline paneel 
sisaldas: CD2, membraani CD3, tsütoplasmiline CD3, CD4, CD5, CD7, CD8, 
CD10, CD11b, CD13, CD14, CD15, CD19, CD20, CD22, CD33, CD34, CD38, 
CD45, CD56, CD65, CD117, anti-müeloperoksüdaas, anti-TdT ja HLA-DR. 
Leukeemia diagnoosimisel koostati igale patsiendile individuaalne leukeemiat 
iseloomustav immuunfenotüüp – kolmevärviline rakumarkerite kombinatsioon, 
mida jälgiti ravi käigus. Minimaalset residuaalset haigust analüüsiti ‘Paint-A-
Gate’ programmi abil. 
Dendriitilisi rakke uuriti neljavärvilise paneeli abil, mis koosnes (1) Lin-
kokteil markerist, mis sisaldas endas rakuliini kuuluvuse näitajaid CD3, CD14, 
CD16, CD19, CD20 ja CD56; (2) CD123; (3) HLA-DR ja (4) CD11c. 
Dendriitiliste rakkude iseloomulikus tunnuseks on HLA-DR tugev positiivsus ja 
liinikuuluvuse markerite puudumine rakupinnal. Plasmatsütoidsed dendriitilised 
rakud on tugevalt CD123 positiivsed, kuid CD11c negatiivsed. Müeloidsed 






Fluorokroomideks antud uurimistöös olid fluorestsiin isothiotsüanaat, fü-
koerüthriin, peridiniin klorofüll proteiin või tandem konjugaat R-fükoerüthriin-




Peennõelbiopsial saadud materjalist saadi immuunfenotüpiseerimisel läbivoolu 
tsütomeetria abil õige diagnoos madalmaliigse B-rakulise mitte-Hodgkini lüm-
foomi korral 95%-l juhtudel, kõrgmaliigse B-rakulise mitte-Hodgkini lümfoomi 
korral 78%-l juhtudel ja T-rakulise lümfoomi korral 53%-l juhtudel. 
Reaktiivne lümfoidne hüperplaasia diagnoositi peennõelbiopsia materjalist 
õigesti 97%-l juhtudest. Seega aitab läbivoolu tsütomeetria usaldusväärselt 
eristada healoomulist reaktiivset põletikulist protsessi pahaloomulistest lüm-
foomidest.  
Kõige olulisem roll oli läbivoolu tsütomeetrial madalmaliigsete B-rakuliste 
lümfoomide diagnoosimisel. Kõrgmaliigsete B-rakuliste lümfoomide diagnosti-
kas on läbivoolu tsütomeetria usaldusväärsus väiksem, sest suured rakud võivad 
biopsia materjali töötlemise käigus hukkuda. Samuti on T-rakuliste lümfoomide 
diagnoosimine ainult rakkude immuunfenotüpiseerimist rakendades proble-
maatiline, sest paljudel juhtudel puudub iseloomulik immuunfenotüüp ja 
puudub ka rakkude klonaalsuse marker. Kui B-rakulistel lümfoomidel puudub 
klonaalsuse marker, siis võib lümfoomi kinnitamisel olla abistavaks uuringuks 
Bcl-2 kvantitatiivne määramine lümfoidsetel rakkudel.  
Meie uuring näitas, et maliigsetes B rakkudes on oluliselt rohkem Bcl-2 
valku kui reaktiivsetes B või T rakkudes. Kõige suurem oli Bcl-2 valgu sisaldus 
follikulaarse lümfoomi rakkudel. Keskmine Bcl-2 eksperssiooni tase, mis oli 
korrigeeritud sama proovi T rakkude suhtes, oli follikulaarse lümfoomi B 
rakkudel 3,69, kuid reaktiivsetel B rakkudel ainult 1,14. Bcl-2 määramine aitas 
kaasa õigele diagnoosile 49 juhul, kui ei leitud selget lümfotsüütide kappa või 
lambda monoklonaalsust või kui lümfoomi rakkudel puudus pinna immuno-
globuliin. 
Minimaalset residuaalset haigust hinnati 43 patsiendil pärast induktsioonravi 
lõppu ja 31 patsiendil keemiaravi järgselt või enne vereloome tüvirakkude 
siirdamist. Mõlemal juhul uuriti minimaalset residuaalset haigust 30 patsiendil. 
Allogeenne siirdamine teostati 16 patsiendil ja autoloogne 15 patsiendil. Paha-
loomuliste blastide hulk ehk minimaalne residuaalne haigus oli keskmiselt 
0,23% kogu luuüdi rakkude arvust nii pärast induktsioonravi lõppu kui 
keemiaravi järgselt või enne siirdamist. Statistiline analüüs näitas üllatuslikult, 
et ägeda müeloidse leukeemiaga patsientidel ei ole minimaalse residuaalse 
haiguse olemasolul prognostilist väärtust. Samas aga määras patsientide prog-
noosi tüvirakkude siirdamine. Seetõttu uurisime ka minimaalse residuaalse 
haiguse seost allogeensesse ja autoloogsesse tüvirakkude siirdamisse. Selleks 
analüüsiks jaotasime patsiendid esmalt nelja rühma: 1. Patsiendid minimaalse 




puudus minimaalne residuaalne haigus, kellele tehti allogeenne siidamise. 3. 
Patsiendid, kellel oli minimaalne residuaalne haigus, kellele ei tehtud 
allogeenset siirdamist ja 4. Patsiendid, kellel puudus minimaalne residuaalne 
haigus ja kellele allogeenset siirdamist ei tehtud. Selgus, et halvim prognoos oli 
patsientidel, kellel oli leitav minimaalne residuaalne haigus, aga kellele 
allogeenset siirdamist ei tehtud. Selles patsientide grupis oli viie aasta jooksul 
haiguse retsidiivideta ainult 20–24% haigetest ja elulemus 34–35%. 
Üllatuslikult näitasid töö tulemused, et minimaalse residuaalse haiguseta ja 
siirdamiseta patsientide elulemus oli samasugune nendega, kellel oli 
minimaalne residuaalne haigus ja kellele tehti allogeenne siirdamine. Üldine 
viie aasta elulemus oli mõlemas patsientide grupis 75%. Nendel patsientidel, 
kellel leiti minimaalne residuaalne haigus induktsioonravi lõppedes, oli viie 
aasta üldiseks elulemuseks 67%, juhul kui teostati allogeenne siirdamine; 46% 
kui teostati autoloogne siirdamine ja 31% kui siirdamist ei teostatud (P = 
0,021). Kui minimaalne residuaalne haigus leiti keemiaravi lõppedes ja 
vereloome tüvirakkude siirdamist ei järgnenud, oli viie aasta elulemuseks vaid 
25%. Patsientidel, kellel tehti allogeenne siirdamine, oli viie aasta elulemuseks 
75%. Kui teostati autoloogne siirdamine, oli elus viie aasta möödudes 53% 
haigetest (P = 0,046).  
Dendriitiliste rakkude uurimisel selgus, et ägeda lümfoblastse leukeemiaga 
lastel on haiguse diagnoosimisel dendriitilisi rakke vähe. Kontrollgrupis oli 
plasmatsütoidsete dendriitiliste rakkude keskmiseks hulgaks 0,28% (0,14–
0,53%) ja müeloidsete dendriitiliste rakkude hulgaks 0,15% (0,10-0,28%) kogu 
luuüdi rakkude arvust. Kõrgriski B-rakulise ägeda leukeemia haigetel 
dendriitlised rakud diagnoosimisel puudusid. Standardriski grupis leiti vähesel 
hulgal plasmatsütoidseid dendriitilisi rakke 30%-l haigetest (keskmiselt 0,03%) 
ja müeloidseid dendriitlisi rakke 22%-l haigetest (keskmiselt 0,015%). 
Keskriski B-rakulise ägeda leukeemia grupis leiti nii plasmatsütoidseid kui 
müeloidseid dendriitilisi rakke 0,01% kogu luuüdi rakkude arvust ainult ühel 28 
patsiendist. Seevastu T-rakulise ägeda leukeemia grupis leiti plasmatsütoidseid 
dendriitilisi rakke 43%-l haigetest (keskmiselt 0,05%) ja müeloidseid 
dendriitilisi rakke 29%-l haigetest (keskmiselt 0,05%). Diagnoosimisel oli T-
rakulise ägeda lümfoblastse leukeemiaga lastel nii plasmatsütoidseid kui 
müeloidseid dendriitilisi rakke statistiliselt rohkem võrreldes B-rakulise 
vormiga, vastavalt P = 0,044 ja P = 0,041.  
Induktsioonravi järgselt olid kõikidel uuritud lastel dendriitilised rakud 
luuüdis leitavad ja nende arv normaliseerus induktsioonravi järgselt 50. ravi-
päevaks (7. ravinädalal). Keskmine plasmatsütoidsete dendriitiliste rakkude arv 
oli induktsioonravi lõppedes T-rakulise ägeda leukeemia grupis 0,33%, 
kõrgriski B-rakulise ägeda leukeemia grupis 0,27%, keskriski grupis 0,22% ja 
standardriski grupis 0,31%. Keskmine müeloidsete dendriitiliste rakkude arv oli 
T-rakulise ägeda leukeemia grupis 0,15%, kõrgriski B-rakulise ägeda leukeemia 
grupis 0,18%, keskriski grupis 0,14% ja standardriski grupis 0,15%. Ravi 




piiridesse. Ka kuus kuud peale ravi tehtud kontrollproovides leiti kõikides 
leukeemia riskigruppides plasmatsütoidseid dendriitilisi rakke normaalsel 
hulgal. Seevastu müeloidsete dendriitiliste rakkude arv langes B-rakulise ägeda 
leukeemia standardriski patsientidel uuesti alla kontrollväärtuse. Kõrgriksi 
patsientidel, kuhu kokku kuulusid T-rakulise ägeda leukeemiaga ja kõrgriski B-
rakulise ägeda leukeemiaga lapsed, jäid müeloidsed dendriitlised rakud 
kontrollväärtuste piiridesse. Leitud erinevus võis olla põhjustatud ravi kestvu-
sest. Ägeda lümfoblastse leukeemia ravi kestis standardriski grupis pool aastat 
kauem – kokku 3 aastat. Kõrgriski grupi ravi kestvuseks oli kaks ja pool aastat. 
Standardriski grupis ei taastunud müeloidsete dendriitiliste rakkude arv ka pool 
aastat pärast ravi lõppu. Kolmel lapsel ei saavutanud 50. ravipäevaks morfo-
loogilist remissiooni. Nendel keemiaravile refraktaarsetel lastel ei täheldatud ka 
dendriitiliste rakkude regeneratsiooni. Ainult ühel lapsel leidsime nii plasma-
tsütoidseid kui müeloidseid dendriitilisi rakke 50. ravipäeval 0,01% kogu luuüdi 
rakkude arvust, teisel kahel lapsel dendriitilisi rakke luuüdis ei leitud.  
 
 
Uurimistööst tulenevad järeldused 
Uurimistöö näitas, et läbivoolu tsütomeetrial on oluline roll mitte-Hodgkini 
lümfoomide õigel diagnoosimisel, lümfoomi täpsema alavormi määramisel ja 
lümfoomide eristamisel reaktiivsest lümfoidsest hüperplaasiast.  
Läbivoolu tsütomeetria abil on võimalik peennõelbiopsia materjalist täpne 
lümfoomide diagnostika 90%-l juhtudest. Bcl-2 lisamine diagnostilisse paneeli 
võimaldab paremini eristada mitte-Hodgkini lümfoomi rakke reaktiivsetest 
lümfoidsetest rakkudest, mis tavaliselt paljunevad infektsiooni korral. Bcl-2 
määramine on abiks eriti nendel juhtudel, kui lümfisõlm on haaratud lüm-
foomist vaid osaliselt, sest siis säilub osaliselt ka lümfisõlme normaalne koeline 
ja rakuline ülesehitus. Kõige olulisem roll on läbivoolu tsütomeetrial madalma-
liigsete lümfoomide diagnoosimisel. Vea võimalus on suurem kõrgmaliigsete 
lümfoomide korral, sest suured pahaloomulised rakud on haprad ja hävivad 
proovi töötlemise käigus. Uurimistöö põhjal võib soovitada osa peennõelbiopsia 
materjalist koheselt kanda uuringuklaasile rakkude vaatamiseks. Kui domi-
neerivateks rakkudeks on väikesed või keskmist suurust lümfotsüüdid, siis on 
soovitav määrata lümfotsüütide immuunfenotüüp läbivoolu tsütomeetrial. Kui 
aga domineerivad suured rakud, on õigem rakkude immuunfenotüpiseerimine 
teostada immuuntsütokeemiliste meetoditega. 
Läbivoolu tsütomeetria võimaldab jälgida minimaalset residuaalset haigust 
90%-l ägeda müeloidse leukeemia patsientidest. Usaldusväärse tulemuse 
saamiseks on vaja jälgida vähemalt kahte või enamat leukeemiale-iseloomu-
likku immuunfenotüüpi. Minimaalse residuaalse haiguse hindamine aitab valida 
kuni 60.a. vanustele patsientidele individuaalse parima induktsioonravi järgse 
raviviisi. Juhul, kui morfoloogilise remissiooni saavutamisel ja/või ravi lõppe-
des on leitavad pahaloomulised müeloidsed blastid ehk minimaalne residuaalne 




siirdamisega. Seega kokkuvõttes võimaldab minimaalse residuaalse haiguse 
määramine parandada patsientide prognoosi, kuid minimaalse residuaalse 
haiguse korral sõltub prognoos siirdamisest. 
Uurides dendriitilisi rakke lastel ägeda lümfoblastse leukeemiaga, leidsime, 
et diagnoosimisel on nende hulk luuüdis märkimisväärselt langenud. Dendriiti-
liste rakkude puudulikkus on enam väljendunud B-rakulise ägeda lümfoblastse 
leukeemia kui T-rakulise ägeda leukeemia korral. B-rakulise ägeda leukeemia 
korral sõltub aga dendriitiliste rakkude arv haiguse raskusest. Nendel lastel, 
kellel haigus oli vähem väljendunud, oli suhteliselt rohkem nii plasma-
tsütoidseid kui müeloidseid dendriitilisi rakke. Ravi käigus taastus dendriitiliste 
rakkude arv normväärtuste piiridesse induktsioonravi lõpuks, seitsme nädala 
möödudes alates ravi algusest. Kuid nendel patsientidel, kellel keemiaravi oli 
efektitu, ei toimunud nii plasmatsütoidsete kui müeloidsete dendriitiliste 
rakkude taastumist, tõenäoliselt leukeemia pärssiva mõju tõttu luuüdi dendriiti-
listele rakkudele. Ravi Põhjamaade laste ägeda lümfoblastse leukeemia ravi-
protokolli NOPHO ALL-2000 järgi mõjutab oluliselt rohkem müeloidseid 
dendriitilisi rakke standardriski grupi lastel. Kui ravi lõppedes plasmatsütoidsed 
dendriitilised rakud jäid normväärtuste piiridesse, siis müeloidsete dendriitiliste 
rakkude arv langes allapoole normväärtusi. Uurimistöö näitas, et müeloidsete 
dendriitiliste rakkude arv ei taastu ka kuus kuud peale ravi lõppemist. Pikaaegne 
ägeda lümfoblastse leukeemia keemiaravi kahjustab müeloidseid dendriitilisi 
rakke ja see kahjustus võib olla üheks immuunsuse languse põhjuseks lastel, kes 
on tervistunud ägedast lümfoidsest leukeemiast. 
Kokkuvõttes näitas uurimistöö, et läbivoolu tsütomeetria on oluline meetod 
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 Rakusurma mehhanismide uurimine lümfoidsetel rakkudel, eelkõige 
glükokortikoidide lüütilisest toimemehhanismist lümfoidsetele rakkudele 
 Läbivoolu tsütomeetria hematoloogias, eelkõige minimaalse residuaalse 
haiguse uurimine ägeda müeloidse leukeemia patsientidel, lümfoomide 
diagnostika ja dentriitiliste rakkude uurimine. 
Kokku 8 artiklit CC ajakirjanduses. 
 
Teaduslike organisatsioonide liikmelisus: 
 Eesti Hematoloogide Seltsi president (2010–) 
 Kesk-Rootsi Leukeemia Grupi liige 





 Põhjamaade Kroonilise Müeloidse Leukeemia Uurimisgrupi liige 
 Hollandi Täiskasvanute Hematoloogia-Onkoloogia Sihtasutuse liige 
 Euroopa Hematoloogia Assotsiatiooni liige 
 
Olen esindanud Eesti Hematoloogide Seltsi Euroopa Hematoloogia Assotsiooni 
H-Net projektis, mille eesmärgiks on harmoniseerida hematoloogide väljaõpet 
Euroopas. Euroopa Hematoloogide Assotsiatsiooni ja Euroopa Hematoloogide 





 Karolinska Haigla, Hematopatoloogia 2000 
 Karolinska Haigla, Hematoloogiakeskus 2001 
 Ateena Lümfoomide ja Leukeemiate täienduskoolitus 2002 
 Euroopa Hematoloogia Assotsiatsiooni Aastakongress 2006–2011 




Teadustöö preemia, I koha Diplom, Tartu Ülikooli Arstiteaduskonna Teadus-
konverents 2005 
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